Editor: NOEL GONZÁLEZ GOTERA Número 065 Diseño: Lic. Roberto Chávez y Liuder Machado. Semana 050113 – 110113 Foto: Lic. Belkis Romeu e Instituto Finlay La Habana, Cuba.
ARTÍCULOS CIENTÍFICOS
P ublicaciones incluidas en P ubMED durante el período comprendido entre el 5 y el 11 de enero de 2013. Con “vaccin*” en título: 112 artículos recuperados.
Vacunas meningococo (Neisseria meningitidis)
17. A dverse events following immunization during mass va ccination campaigns at first i ntroduction of a meningococcal A conjugate va ccine in Burkina Faso, 2010.
Ouandaogo CR, Yaméogo TM, Diomandé FV, Sawadogo C, Ouédraogo B, Ouédraogo-Traoré R, Pezzoli L, Djingarey MH, Mbakuliyemo N, Zuber PL.
Vaccine. 2012 May 30;30 Suppl 2:B46-51. doi: 10.1016/j.vaccine.2011.12.112. Epub 2012 Jan 9.
PMID: 22230584 [PubMed - indexed for MEDLINE]
Related citations
20. The challenge of post-implementation surveillance for novel meningococcal va ccines.
Snape MD, Medini D, Halperin SA, DeTora L, Drori J, Moxon ER.
Vaccine. 2012 May 30;30 Suppl 2:B67-72. doi: 10.1016/j.vaccine.2011.12.126. Epub 2012 Jan 9. Review.
PMID: 22230578 [PubMed - indexed for MEDLINE]
Related citations
1 Vacunas BCG – ONCO BCG (Mycobacterium bovis)
49. The effect of passages during Japanese BCG va ccine production on genetic stability and protective efficacy.
Seki M, Udagawa T, Sugawara I, Iwama K, Honda I, Fujita I, Hashimoto A, Yano I, Yamamoto S.
Vaccine. 2012 Feb 14;30(8):1460-4. doi: 10.1016/j.vaccine.2011.12.101. Epub 2012 Jan 5.
PMID: 22226863 [PubMed - indexed for MEDLINE]
Related citations
Vacunas neumococo (Streptococcus pneumoniae)
38. P neumococcal bacteremia in a va ccinated pediatric sickle cell disease population.
Ellison AM, Ota KV, McGowan KL, Smith-Whitley K.
Pediatr Infect Dis J. 2012 May;31(5):534-6. doi: 10.1097/INF.0b013e3182480fed.
PMID: 22228232 [PubMed - indexed for MEDLINE]
Related citations
Vacuna tosferina (Bordetella pertussis)
58. R ecommended or mandatory pertussis va ccination policy in developed countries: does the choice matter?
Girard DZ.
Public Health. 2012 Feb;126(2):117-22. doi: 10.1016/j.puhe.2011.11.007. Epub 2012 Jan 5.
PMID: 22226337 [PubMed - indexed for MEDLINE]
Related citations
Vacunas Adjuvantes
14. A ntigen delivery for cross priming via the emulsion va ccine adjuvants.
Shen SS, Yang YW.
Vaccine. 2012 Feb 21;30(9):1560-71. doi: 10.1016/j.vaccine.2011.12.120. Epub 2012 Jan 9.
PMID: 22230588 [PubMed - indexed for MEDLINE]
Related citations
2 Vacunas cólera (Vibrio cholerae)
1. Ha iti prepares for cholera va ccination but concerns remain.
Adams P.
Lancet. 2012 Jan 7;379(9810):16. No abstract available. Erratum in: Lancet. 2012 Mar 24;379(9821):1102.
PMID: 22232798 [PubMed - indexed for MEDLINE]
Related citations
Vacunas, otras
1.
H aiti prepares for cholera va ccination but concerns remain.
Adams P.
Lancet. 2012 Jan 7;379(9810):16. No abstract available. Erratum in: Lancet. 2012 Mar 24;379(9821):1102.
PMID: 22232798 [PubMed - indexed for MEDLINE]
Related citations
2.
A n adverse event following 2009 H1N1 influenza va ccination: a case of acute disseminated encephalomyelitis.
Lee ST, Choe YJ, Moon WJ, Choi JW, Lee R.
Korean J Pediatr. 2011 Oct;54(10):422-4. doi: 10.3345/kjp.2011.54.10.422. Epub 2011 Oct 31.
PMID: 22232625 [PubMed] Free PMC Article
Related citations
3.
3 Methodological issues with the risk of relapse study in patients with multiple sclerosis a fter yellow fever va ccination.
Pool V, Gordon DM, Decker M.
Arch Neurol. 2012 Jan;69(1):144; author reply 144-5. doi: 10.1001/archneurol.2011.1519. No abstract available.
PMID: 22232361 [PubMed - indexed for MEDLINE]
Related citations
4.
T he risk of immune thrombocytopenic purpura after va ccination in children and adolescents.
O'Leary ST, Glanz JM, McClure DL, Akhtar A, Daley MF, Nakasato C, Baxter R, Davis RL, Izurieta HS, Lieu TA, Ball R.
Pediatrics. 2012 Feb;129(2):248-55. doi: 10.1542/peds.2011-1111. Epub 2012 Jan 9.
PMID: 22232308 [PubMed - indexed for MEDLINE]
Related citations
5.
Immune senescence in old and very old rhesus monkeys: reduced antibody response to influenza va ccination.
Coe CL, Lubach GR, Kinnard J.
Age (Dordr). 2012 Oct;34(5):1169-77. Epub 2012 Jan 10.
PMID: 22231440 [PubMed - in process]
Related citations
6.
S tructural va ccinology: structure-based design of influenza A virus hemagglutinin s ubtype-specific subunit va ccines.
Xuan C, Shi Y, Qi J, Zhang W, Xiao H, Gao GF.
4 Protein Cell. 2011 Dec;2(12):997-1005. doi: 10.1007/s13238-011-1134-y. Epub 2012 Jan 10. Erratum in: Protein Cell. 2012 Feb;3(2):160.
PMID: 22231357 [PubMed - indexed for MEDLINE]
Related citations
7.
Mitigation of pyrexia by a Th-1-biased IgG subclass response after infection with e quine herpesvirus type 1 in horses pre-immunized with inactivated va ccine.
Bannai H, Tsujimura K, Kondo T, Nemoto M, Yamanaka T, Sugiura T, Kato T, Maeda K, Matsumura T.
J Vet Med Sci. 2012 Jun;74(6):791-5. Epub 2012 Jan 10.
PMID: 22230983 [PubMed - indexed for MEDLINE] Free Article
Related citations
8.
Cutaneous cytomegalovirus infection in a child with hyper IgE and specific defects in a ntibody response to protein va ccines.
Fallah S, Tabatabaei A, Pournasir Z, Chavoshzadeh Z, Rezaei N.
Braz J Infect Dis. 2011 Sep-Oct;15(5):484-5.
PMID: 22230858 [PubMed - indexed for MEDLINE] Free Article
Related citations
9.
Characterizing providers' immunization communication practices during health s upervision visits with va ccine- hesitant parents: a pilot study.
Opel DJ, Robinson JD, Heritage J, Korfiatis C, Taylor JA, Mangione-Smith R.
Vaccine. 2012 Feb 8;30(7):1269-75. doi: 10.1016/j.vaccine.2011.12.129. Epub 2012 Jan 9.
PMID: 22230593 5 [PubMed - in process]
Related citations
10.
C linical study of transcutaneous va ccination using a hydrogel patch for tetanus and diphtheria.
Hirobe S, Matsuo K, Quan YS, Kamiyama F, Morito H, Asada H, Takaya Y, Mukai Y, Okada N, Nakagawa S.
Vaccine. 2012 Feb 27;30(10):1847-54. doi: 10.1016/j.vaccine.2011.12.130. Epub 2012 Jan 9.
PMID: 22230592 [PubMed - indexed for MEDLINE]
Related citations
11.
H ealth-related quality of life in the Anthrax V accination Program for workers in the Laboratory Response Network.
Stewart B, Zhang Y, Rose CE Jr, Tokars JI, Martin SW, Franzke LH, McNeil MM.
Vaccine. 2012 Feb 27;30(10):1841-6. doi: 10.1016/j.vaccine.2011.12.128. Epub 2012 Jan 9.
PMID: 22230591 [PubMed - indexed for MEDLINE]
Related citations
12.
U .K. parents' decision-making about measles-mumps-rubella (MMR) va ccine 10 years after the MMR-autism controversy: a qualitative analysis.
Brown KF, Long SJ, Ramsay M, Hudson MJ, Green J, Vincent CA, Kroll JS, Fraser G, Sevdalis N.
Vaccine. 2012 Feb 27;30(10):1855-64. doi: 10.1016/j.vaccine.2011.12.127. Epub 2012 Jan 9.
PMID: 22230590 [PubMed - indexed for MEDLINE]
Related citations
6 13.
M ucosal va ccination increases local chemokine production attracting immune cells to the stomach mucosa of Helicobacter pylori infected mice.
Flach CF, Mozer M, Sundquist M, Holmgren J, Raghavan S.
Vaccine. 2012 Feb 21;30(9):1636-43. doi: 10.1016/j.vaccine.2011.12.111. Epub 2012 Jan 9.
PMID: 22230589 [PubMed - indexed for MEDLINE]
Related citations
14.
A ntigen delivery for cross priming via the emulsion va ccine adjuvants.
Shen SS, Yang YW.
Vaccine. 2012 Feb 21;30(9):1560-71. doi: 10.1016/j.vaccine.2011.12.120. Epub 2012 Jan 9.
PMID: 22230588 [PubMed - indexed for MEDLINE]
Related citations
15.
Geographic differentiation of polymorphism in the Plasmodium falciparum malaria va ccine candidate gene SERA5.
Tanabe K, Arisue N, Palacpac NM, Yagi M, Tougan T, Honma H, Ferreira MU, Färnert A, Björkman A, Kaneko A, Nakamura M, Hirayama K, Mita T, Horii T.
Vaccine. 2012 Feb 21;30(9):1583-93. doi: 10.1016/j.vaccine.2011.12.124. Epub 2012 Jan 9.
PMID: 22230587 [PubMed - indexed for MEDLINE]
Related citations
16.
A genomics-based approach to assessment of va ccine safety and immunogenicity in children.
7 White OJ, McKenna KL, Bosco A, H J van den Biggelaar A, Richmond P, Holt PG.
Vaccine. 2012 Feb 27;30(10):1865-74. doi: 10.1016/j.vaccine.2011.12.118. Epub 2012 Jan 9.
PMID: 22230586 [PubMed - indexed for MEDLINE]
Related citations
17.
A dverse events following immunization during mass va ccination campaigns at first i ntroduction of a meningococcal A conjugate va ccine in Burkina Faso, 2010.
Ouandaogo CR, Yaméogo TM, Diomandé FV, Sawadogo C, Ouédraogo B, Ouédraogo- Traoré R, Pezzoli L, Djingarey MH, Mbakuliyemo N, Zuber PL.
Vaccine. 2012 May 30;30 Suppl 2:B46-51. doi: 10.1016/j.vaccine.2011.12.112. Epub 2012 Jan 9.
PMID: 22230584 [PubMed - indexed for MEDLINE]
Related citations
18.
V accination of healthy and diseased koalas (Phascolarctos cinereus) with a Chlamydia p ecorum multi-subunit va ccine: evaluation of immunity and pathology.
Kollipara A, George C, Hanger J, Loader J, Polkinghorne A, Beagley K, Timms P.
Vaccine. 2012 Feb 27;30(10):1875-85. doi: 10.1016/j.vaccine.2011.12.125. Epub 2012 Jan 9.
PMID: 22230583 [PubMed - indexed for MEDLINE]
Related citations
19.
Cloned cDNA of A/swine/Iowa/15/1930 internal genes as a candidate backbone for r everse genetics va ccine against influenza A viruses.
Lekcharoensuk P, Wiriyarat W, Petcharat N, Lekcharoensuk C, Auewarakul P, Richt JA.
Vaccine. 2012 Feb 14;30(8):1453-9. doi: 10.1016/j.vaccine.2011.12.109. Epub 2012 Jan 9.
8 PMID: 22230579 [PubMed - indexed for MEDLINE]
Related citations
20.
T he challenge of post-implementation surveillance for novel meningococcal va ccines.
Snape MD, Medini D, Halperin SA, DeTora L, Drori J, Moxon ER.
Vaccine. 2012 May 30;30 Suppl 2:B67-72. doi: 10.1016/j.vaccine.2011.12.126. Epub 2012 Jan 9. Review.
PMID: 22230578 [PubMed - indexed for MEDLINE]
Related citations
21.
[ The efficacy of enhancing murine zona pellucid 3 DNA va ccine immunized through i ntranasal va ccination by IL-15].
Liu FP, Chang D, Yu YK, Zhang FC, Zhang AL.
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2012 Jan;28(1):25-8. Chinese.
PMID: 22230499 [PubMed - indexed for MEDLINE]
Related citations
22.
A review of malaria va ccine clinical projects based on the WHO rainbow table.
Schwartz L, Brown GV, Genton B, Moorthy VS.
Malar J. 2012 Jan 9;11:11. doi: 10.1186/1475-2875-11-11. Review.
PMID: 22230255 [PubMed - indexed for MEDLINE] Free PMC Article
Related citations
23.
9 R ace and sexual behavior predict uptake of the human papillomavirus va ccine.
Keenan K, Hipwell A, Stepp S.
Health Psychol. 2012 Jan;31(1):31-4. doi: 10.1037/a0026812.
PMID: 22229933 [PubMed - indexed for MEDLINE] Free PMC Article
Related citations
24.
Reported adverse events in young women following quadrivalent human p apillomavirus va ccination.
Naleway AL, Gold R, Drew L, Riedlinger K, Henninger ML, Gee J.
J Womens Health (Larchmt). 2012 Apr;21(4):425-32. doi: 10.1089/jwh.2011.2895. Epub 2012 Jan 9.
PMID: 22229713 [PubMed - indexed for MEDLINE]
Related citations
25.
Ps eudoseptic arthritis of the shoulder following pneumococcal va ccination.
Floyd MW, Boyce BM, Castellan RM, McDonough EB.
Orthopedics. 2012 Jan 16;35(1):e101-3. doi: 10.3928/01477447-20111122-31.
PMID: 22229599 [PubMed - indexed for MEDLINE]
Related citations
26.
A nti-cocaine va ccine based on coupling a cocaine analog to a disrupted adenovirus.
Koob G, Hicks MJ, Wee S, Rosenberg JB, De BP, Kaminsky SM, Moreno A, Janda KD, Crystal RG.
CNS Neurol Disord Drug Targets. 2011 Dec;10(8):899-904. Review.
PMID:
10 22229312 [PubMed - indexed for MEDLINE] Free PMC Article
Related citations
27.
D eveloping a va ccine against multiple psychoactive targets: a case study of heroin.
Stowe GN, Schlosburg JE, Vendruscolo LF, Edwards S, Misra KK, Schulteis G, Zakhari JS, Koob GF, Janda KD.
CNS Neurol Disord Drug Targets. 2011 Dec;10(8):865-75. Review.
PMID: 22229311 [PubMed - indexed for MEDLINE] Free PMC Article
Related citations
28.
N icotine va ccines.
Fahim RE, Kessler PD, Fuller SA, Kalnik MW.
CNS Neurol Disord Drug Targets. 2011 Dec;10(8):905-15. Review.
PMID: 22229310 [PubMed - indexed for MEDLINE]
Related citations
29.
R ational Design of V accines to Elicit Broadly Neutralizing Antibodies to HIV-1.
Kwong PD, Mascola JR, Nabel GJ.
Cold Spring Harb Perspect Med. 2011 Sep;1(1):a007278. doi: 10.1101/cshperspect.a007278.
PMID: 22229123 [PubMed] Free PMC Article
Related citations
30.
11 V accine design for CD8 T lymphocyte responses.
Koup RA, Douek DC.
Cold Spring Harb Perspect Med. 2011 Sep;1(1):a007252. doi: 10.1101/cshperspect.a007252.
PMID: 22229122 [PubMed] Free PMC Article
Related citations
31.
Fa ctors Affecting Intention among Students to Be V accinated against A/H1N1 Influenza: A Health Belief Model Approach.
Teitler-Regev S, Shahrabani S, Benzion U.
Adv Prev Med. 2011;2011:353207. doi: 10.4061/2011/353207. Epub 2011 Dec 20.
PMID: 22229099 [PubMed] Free PMC Article
Related citations
32.
I mmune modulation in primary va ccinia virus zoonotic human infections.
Silva Gomes JA, de Araújo FF, de Souza Trindade G, Quinan BR, Drumond BP, Ferreira JM, Mota BE, Nogueira ML, Kroon EG, Santos Abrahão J, Côrrea-Oliveira R, da Fonseca FG.
Clin Dev Immunol. 2012;2012:974067. doi: 10.1155/2012/974067. Epub 2011 Dec 20.
PMID: 22229039 [PubMed - indexed for MEDLINE] Free PMC Article
Related citations
33.
V accination against bluetongue.
[No authors listed]
12 Vet Rec. 2012 Jan 7;170(1):16. doi: 10.1136/vr.e24. No abstract available.
PMID: 22228865 [PubMed - indexed for MEDLINE]
Related citations
34.
CCL19 (ELC) improves TH1-polarized immune responses and protective immunity in a m urine Her2/neu DNA va ccination model.
Nguyen-Hoai T, Baldenhofer G, Ahmed MS, Pham-Duc M, Gries M, Lipp M, Dörken B, Pezzutto A, Westermann J.
J Gene Med. 2012 Feb;14(2):128-37. doi: 10.1002/jgm.1651.
PMID: 22228591 [PubMed - indexed for MEDLINE]
Related citations
35.
C D40-targeted adenoviral cancer va ccines: the long and winding road to the clinic.
Hangalapura BN, Timares L, Oosterhoff D, Scheper RJ, Curiel DT, de Gruijl TD.
J Gene Med. 2012 Jun;14(6):416-27. doi: 10.1002/jgm.1648. Review.
PMID: 22228547 [PubMed - indexed for MEDLINE]
Related citations
36.
A cceptance and opinions of Intanza/IDflu intradermal influenza va ccine in the Czech Republic and Turkey.
Prymula R, Usluer G, Altinel S, Sichova R, Weber F.
Adv Ther. 2012 Jan;29(1):41-52. doi: 10.1007/s12325-011-0090-5. Epub 2012 Jan 3.
PMID: 22228256 [PubMed - indexed for MEDLINE]
Related citations
13 37.
Effi cacy and immunogenicity of live-attenuated human rotavirus va ccine in breast-fed and formula-fed European infants.
Vesikari T, Prymula R, Schuster V, Tejedor JC, Cohen R, Bouckenooghe A, Damaso S, Han HH.
Pediatr Infect Dis J. 2012 May;31(5):509-13. doi: 10.1097/INF.0b013e3182489cac.
PMID: 22228235 [PubMed - indexed for MEDLINE]
Related citations
38.
Pn eumococcal bacteremia in a va ccinated pediatric sickle cell disease population.
Ellison AM, Ota KV, McGowan KL, Smith-Whitley K.
Pediatr Infect Dis J. 2012 May;31(5):534-6. doi: 10.1097/INF.0b013e3182480fed.
PMID: 22228232 [PubMed - indexed for MEDLINE]
Related citations
39.
S afety, reactogenicity and immunogenicity of the human rotavirus va ccine in preterm European Infants: a randomized phase IIIb study.
Omenaca F, Sarlangue J, Szenborn L, Nogueira M, Suryakiran PV, Smolenov IV, Han HH; ROTA-054 Study Group.
Pediatr Infect Dis J. 2012 May;31(5):487-93. doi: 10.1097/INF.0b013e3182490a2c.
PMID: 22228231 [PubMed - indexed for MEDLINE]
Related citations
40.
Pr otective antibody responses to influenza A/H1N1/09 va ccination in children with celiac disease.
Schäppi MG, Meier S, Bel M, Siegrist CA, Posfay-Barbe KM; H1N1 Study Group.
14 J Pediatr Gastroenterol Nutr. 2012 Jun;54(6):817-9. doi: 10.1097/MPG.0b013e318248e7be.
PMID: 22228003 [PubMed - indexed for MEDLINE]
Related citations
41.
C omparison of knowledge and attitudes toward human papillomavirus, HPV va ccine, pap tests, and cervical cancer between US and Peruvian women.
Han CS, Ferris DG, Waller J, Tharp P, Walter J, Allmond L.
J Low Genit Tract Dis. 2012 Apr;16(2):121-6. doi: 10.1097/LGT.0b013e31823a05a3.
PMID: 22227842 [PubMed - indexed for MEDLINE]
Related citations
42.
T he value of HPV va ccination.
[No authors listed]
Nat Med. 2012 Jan 6;18(1):28-9. doi: 10.1038/nm0112-28. No abstract available.
PMID: 22227663 [PubMed - indexed for MEDLINE]
Related citations
43.
S afety and immunogenicity of a modified process hepatitis B va ccine in healthy neonates.
Minervini G, McCarson BJ, Reisinger KS, Martin JC, Stek JE, Atkins BM, Nadig KB, Liska V, Schödel FP, Bhuyan PK.
Vaccine. 2012 Feb 14;30(8):1476-80. doi: 10.1016/j.vaccine.2011.12.095. Epub 2012 Jan 5.
PMID: 22227229 [PubMed - indexed for MEDLINE]
15 Related citations
44.
V accination coverage in Haiti: results from the 2009 national survey.
Rainey JJ, Lacapère F, Danovaro-Holliday MC, Mung K, Magloire R, Kananda G, Cadet JR, Lee CE, Chamouillet H, Luman ET.
Vaccine. 2012 Feb 21;30(9):1746-51. doi: 10.1016/j.vaccine.2011.12.015. Epub 2012 Jan 3.
PMID: 22227146 [PubMed - indexed for MEDLINE]
Related citations
45.
V accinia virus-induced smallpox postvaccinal encephalitis in case of blood-brain barrier damage.
Garcel A, Fauquette W, Dehouck MP, Crance JM, Favier AL.
Vaccine. 2012 Feb 8;30(7):1397-405. doi: 10.1016/j.vaccine.2011.08.116. Epub 2012 Jan 9.
PMID: 22227123 [PubMed - in process]
Related citations
46.
C omparative protection of two different commercial va ccines against Yersinia ruckeri serotype O1 and biotype 2 in rainbow trout (Oncorhynchus mykiss).
Deshmukh S, Raida MK, Dalsgaard I, Chettri JK, Kania PW, Buchmann K.
Vet Immunol Immunopathol. 2012 Jan 15;145(1-2):379-85. doi: 10.1016/j.vetimm.2011.12.014. Epub 2011 Dec 21.
PMID: 22227075 [PubMed - indexed for MEDLINE]
Related citations
47.
I nfluenza va ccine and healthcare workers.
16 Aguilar-Díaz Fdel C, Jiménez-Corona ME, Ponce-de-León-Rosales S.
Arch Med Res. 2011 Nov;42(8):652-7. doi: 10.1016/j.arcmed.2011.12.006. Epub 2012 Jan 4. Review.
PMID: 22227045 [PubMed - indexed for MEDLINE]
Related citations
48.
Characterization of germline antibody libraries from human umbilical cord blood and selection of monoclonal antibodies to viral envelope glycoproteins: Implications for m echanisms of immune evasion and design of va ccine immunogens.
Chen W, Streaker ED, Russ DE, Feng Y, Prabakaran P, Dimitrov DS.
Biochem Biophys Res Commun. 2012 Jan 27;417(4):1164-9. doi: 10.1016/j.bbrc.2011.12.089. Epub 2011 Dec 27.
PMID: 22226962 [PubMed - indexed for MEDLINE]
Related citations
49.
T he effect of passages during Japanese BCG va ccine production on genetic stability and protective efficacy.
Seki M, Udagawa T, Sugawara I, Iwama K, Honda I, Fujita I, Hashimoto A, Yano I, Yamamoto S.
Vaccine. 2012 Feb 14;30(8):1460-4. doi: 10.1016/j.vaccine.2011.12.101. Epub 2012 Jan 5.
PMID: 22226863 [PubMed - indexed for MEDLINE]
Related citations
50.
I ntrinsic adjuvanting of a novel single-cycle flavivirus va ccine in the absence of type I interferon receptor signaling.
Winkelmann ER, Widman DG, Xia J, Ishikawa T, Miller-Kittrell M, Nelson MH, Bourne N, Scholle F, Mason PW, Milligan GN.
17 Vaccine. 2012 Feb 14;30(8):1465-75. doi: 10.1016/j.vaccine.2011.12.103. Epub 2012 Jan 5.
PMID: 22226862 [PubMed - indexed for MEDLINE]
Related citations
51.
Public health impact of including two lineages of influenza B in a quadrivalent seasonal i nfluenza va ccine.
Reed C, Meltzer MI, Finelli L, Fiore A.
Vaccine. 2012 Mar 2;30(11):1993-8. doi: 10.1016/j.vaccine.2011.12.098. Epub 2012 Jan 5.
PMID: 22226861 [PubMed - indexed for MEDLINE]
Related citations
52.
C onfounding and bias in studies of DMSS va ccination data.
Nevin RL.
Vaccine. 2012 Nov 26;30(50):7146. doi: 10.1016/j.vaccine.2011.12.100. Epub 2012 Jan 5. No abstract available.
PMID: 22226860 [PubMed - in process]
Related citations
53.
M edicaid reimbursement and the uptake of adolescent va ccines.
Gowda C, Dempsey AF.
Vaccine. 2012 Feb 21;30(9):1682-9. doi: 10.1016/j.vaccine.2011.12.097. Epub 2012 Jan 5.
PMID: 22226859 [PubMed - indexed for MEDLINE]
18 Related citations
54.
A dult va ccination in 11 Central European countries - calendars are not just for children.
Chlibek R, Anca I, André F, Čižman M, Ivaskeviciene I, Mangarov A, Mészner Z, Perenovska P, Pokorn M, Prymula R, Richter D, Salman N, Šimurka P, Tamm E, Tešović G, Urbancikova I, Zavadska D, Usonis V.
Vaccine. 2012 Feb 21;30(9):1529-40. doi: 10.1016/j.vaccine.2011.12.091. Epub 2012 Jan 5. Review.
PMID: 22226858 [PubMed - indexed for MEDLINE]
Related citations
55.
PEGy lated cationic liposomes robustly augment va ccine- induced immune responses: Role of lymphatic trafficking and biodistribution.
Zhuang Y, Ma Y, Wang C, Hai L, Yan C, Zhang Y, Liu F, Cai L.
J Control Release. 2012 Apr 10;159(1):135-42. doi: 10.1016/j.jconrel.2011.12.017. Epub 2011 Dec 29.
PMID: 22226776 [PubMed - indexed for MEDLINE]
Related citations
56.
V accinia viruses isolated from cutaneous disease in horses are highly virulent for rabbits.
Felipetto Cargnelutti J, Schmidt C, Masuda EK, Braum LD, Weiblen R, Furtado Flores E.
Microb Pathog. 2012 Mar;52(3):192-9. doi: 10.1016/j.micpath.2011.12.005. Epub 2011 Dec 29.
PMID: 22226666 [PubMed - indexed for MEDLINE]
Related citations
57.
19 S almonella flagellin enhances mucosal immunity of avian influenza va ccine in chickens.
Chaung HC, Cheng LT, Hung LH, Tsai PC, Skountzou I, Wang B, Compans RW, Lien YY.
Vet Microbiol. 2012 May 25;157(1-2):69-77. doi: 10.1016/j.vetmic.2011.12.014. Epub 2011 Dec 16.
PMID: 22226542 [PubMed - indexed for MEDLINE]
Related citations
58.
R ecommended or mandatory pertussis va ccination policy in developed countries: does the choice matter?
Girard DZ.
Public Health. 2012 Feb;126(2):117-22. doi: 10.1016/j.puhe.2011.11.007. Epub 2012 Jan 5.
PMID: 22226337 [PubMed - indexed for MEDLINE]
Related citations
59.
Perceptions of participating emergency nurses regarding an ED seasonal influenza va ccination program.
Venkat A, Hunter R, Hegde GG, Chan-Tompkins NH, Chuirazzi DM, Szczesiul JM.
J Emerg Nurs. 2012 Jan;38(1):22-9. doi: 10.1016/j.jen.2010.08.015. Epub 2010 Oct 15.
PMID: 22226133 [PubMed - indexed for MEDLINE]
Related citations
60.
[ Relationship between precariousness, social coverage, and va ccine coverage: survey among children consulting in pediatric emergency departments in France].
Bouhamam N, Laporte R, Boutin A, Uters M, Bremond V, Noel G, Rodier P, Minodier P.
20 Arch Pediatr. 2012 Mar;19(3):242-7. doi: 10.1016/j.arcped.2011.12.001. Epub 2012 Jan 4. French.
PMID: 22226013 [PubMed - indexed for MEDLINE]
Related citations
61.
Micro-Dissecting the Pathogenesis and Immune Response of PRRSV Infection Paves th e Way for More Efficient PRRSV V accines.
Nauwynck HJ, Van Gorp H, Vanhee M, Karniychuk U, Geldhof M, Cao A, Verbeeck M, Van Breedam W.
Transbound Emerg Dis. 2012 Jan 9. doi: 10.1111/j.1865-1682.2011.01292.x. [Epub ahead of print]
PMID: 22225918 [PubMed - as supplied by publisher]
Related citations
62.
Effe ct of challenge of pigs previously immunised with inactivated va ccines containing homologous and heterologous Mycoplasma hyopneumoniae strains.
Villarreal I, Vranckx K, Calus D, Pasmans F, Haesebrouck F, Maes D.
BMC Vet Res. 2012 Jan 6;8:2. doi: 10.1186/1746-6148-8-2.
PMID: 22225838 [PubMed - indexed for MEDLINE] Free PMC Article
Related citations
63.
T he new decade of va ccines.
Hachey K.
Lancet. 2012 Jan 7;379(9810):27. doi: 10.1016/S0140-6736(12)60018-X. No abstract available.
PMID: 22225665 [PubMed - indexed for MEDLINE] 21 Related citations
64.
T he new decade of va ccines.
Shann F.
Lancet. 2012 Jan 7;379(9810):26; author reply 27. doi: 10.1016/S0140- 6736(12)60016-6. No abstract available.
PMID: 22225662 [PubMed - indexed for MEDLINE]
Related citations
65.
T he new decade of va ccines.
Aaby P, Martins C, Benn CS, Whittle H.
Lancet. 2012 Jan 7;379(9810):25-6; author reply 27. doi: 10.1016/S0140- 6736(12)60015-4. No abstract available.
PMID: 22225660 [PubMed - indexed for MEDLINE]
Related citations
66.
I mmune responses to mucosal va ccination by the recombinant A1 and N proteins of infectious bronchitis virus.
Meir R, Krispel S, Simanov L, Eliahu D, Maharat O, Pitcovski J.
Viral Immunol. 2012 Feb;25(1):55-62. doi: 10.1089/vim.2011.0050. Epub 2012 Jan 6.
PMID: 22225471 [PubMed - indexed for MEDLINE]
Related citations
67.
H istory and development of haemophilus influenzae type B va ccine.
[No authors listed]
22 Pediatr Ann. 2012 Jan;41(1):38-9. doi: 10.3928/00904481-20111209-11. No abstract available.
PMID: 22224719 [PubMed - in process]
Related citations
68.
N ew hepatitis B va ccine schedule for children with celiac disease.
Leonardi S, Miraglia Del Giudice M, La Rosa M.
Hepat Mon. 2011 Oct;11(10):850-1. doi: 10.5812/kowsar.1735143x.772. No abstract available.
PMID: 22224087 [PubMed] Free PMC Article
Related citations
69.
Effi cacy of HBV va ccination in various stages of chronic kidney disease: is earlier better?
Hashemi B, Mahdavi-Mazdeh M, Abbasi M, Hosseini-Moghaddam SM, Zinat NH, Ahmadi F.
Hepat Mon. 2011 Oct;11(10):816-20. doi: 10.5812/kowsar.1735143X.751.
PMID: 22224080 [PubMed] Free PMC Article
Related citations
70.
I mmune response to hepatitis B va ccine in patients with chronic kidney disease.
Einollahi B.
Hepat Mon. 2011 Oct;11(10):781-2. doi: 10.5812/kowsar.1735143x.766. No abstract available.
PMID: 22224074 [PubMed] 23 Free PMC Article
Related citations
71.
" To use or not to use"- dilemma of developing countries in introducing new va ccines.
Babu GR, Murthy G.
J Glob Infect Dis. 2011 Oct;3(4):406-7. doi: 10.4103/0974-777X.91071. No abstract available.
PMID: 22224011 [PubMed] Free PMC Article
Related citations
72.
Reactions of Norwegian children with severe egg allergy to an egg-containing i nfluenza A (H1N1) va ccine: a retrospective audit.
Forsdahl BA.
BMJ Open. 2012 Jan 5;2:e000186. doi: 10.1136/bmjopen-2011-000186. Print 2012.
PMID: 22223837 [PubMed] Free PMC Article
Related citations
73.
A dvertisements promoting human papillomavirus va ccine for adolescent boys: does source matter?
Pepper JK, Reiter PL, McRee AL, Brewer NT.
Sex Transm Infect. 2012 Jun;88(4):264-5. doi: 10.1136/sextrans-2011-050197. Epub 2012 Jan 4.
PMID: 22223814 [PubMed - indexed for MEDLINE]
Related citations
74.
24 A va ccine candidate for eastern equine encephalitis virus based on IRES-mediated attenuation.
Pandya J, Gorchakov R, Wang E, Leal G, Weaver SC.
Vaccine. 2012 Feb 8;30(7):1276-82. doi: 10.1016/j.vaccine.2011.12.121. Epub 2012 Jan 2.
PMID: 22222869 [PubMed - in process]
Related citations
75.
Evo lution of MS lesions to black holes under DNA va ccine treatment.
Papadopoulou A, von Felten S, Traud S, Rahman A, Quan J, King R, Garren H, Steinman L, Cutter G, Kappos L, Radue EW.
J Neurol. 2012 Jul;259(7):1375-82. doi: 10.1007/s00415-011-6361-x. Epub 2012 Jan 6.
PMID: 22222856 [PubMed - indexed for MEDLINE]
Related citations
76.
A DNA va ccine co-expressing Trichinella spiralis MIF and MCD-1 with murine ubiquitin induces partial protective immunity in mice.
Tang F, Xu L, Yan R, Song X, Li X.
J Helminthol. 2012 Jan 5:1-10. [Epub ahead of print]
PMID: 22221593 [PubMed - as supplied by publisher]
Related citations
77.
S chools as potential va ccination venue for va ccines outside regular EPI schedule: results from a school census in Pakistan.
Soofi SB, Haq IU, Khan MI, Siddiqui MB, Mirani M, Tahir R, Hussain I, Puri MK, Suhag ZH, Khowaja AR, Lasi AR, Clemens JD, Favorov M, Ochiai RL, Bhutta ZA.
25 BMC Res Notes. 2012 Jan 6;5:6. doi: 10.1186/1756-0500-5-6.
PMID: 22221404 [PubMed] Free PMC Article
Related citations
78.
Fi rst clinical trial of cancer va ccine therapy with artificially synthesized helper/ k iller- hybrid epitope long peptide of MAGE-A4 cancer antigen.
Takahashi N, Ohkuri T, Homma S, Ohtake J, Wakita D, Togashi Y, Kitamura H, Todo S, Nishimura T.
Cancer Sci. 2012 Jan;103(1):150-3. doi: 10.1111/j.1349-7006.2011.02106.x.
PMID: 22221328 [PubMed - indexed for MEDLINE]
Related citations
79.
T olerogenic DNA va ccine for prevention of autoimmune ovarian disease.
Kang Y, Zheng G, Chen A, Wang J, Hu Y, Li J, Zhang J, Gao W, Fu H, Xia G, Wang B.
Immunol Invest. 2012;41(3):249-60. doi: 10.3109/08820139.2011.622828. Epub 2012 Jan 5.
PMID: 22221010 [PubMed - indexed for MEDLINE]
Related citations
80.
Eva luation of attenuated VSVs with mutated M or/and G proteins as va ccine vectors.
Fang X, Zhang S, Sun X, Li J, Sun T.
Vaccine. 2012 Feb 8;30(7):1313-21. doi: 10.1016/j.vaccine.2011.12.085. Epub 2012 Jan 2.
26 PMID: 22222871 [PubMed - in process]
Related citations
81.
H PV va ccine is now routinely indicated for males.
Campos-Outcalt D.
J Fam Pract. 2012 Jan;61(1):38-40. No abstract available.
PMID: 22220294 [PubMed - indexed for MEDLINE]
Related citations
82.
C utting edge: Protective effect of CX3CR1+ dendritic cells in a va ccinia virus pulmonary infection model.
Bonduelle O, Duffy D, Verrier B, Combadière C, Combadière B.
J Immunol. 2012 Feb 1;188(3):952-6. doi: 10.4049/jimmunol.1004164. Epub 2012 Jan 4.
PMID: 22219332 [PubMed - indexed for MEDLINE]
Related citations
83.
A reduced-dose seasonal trivalent influenza va ccine is safe and immunogenic in adult and elderly patients in a randomized controlled trial.
Vajo Z, Tamas F, Jankovics I.
Clin Vaccine Immunol. 2012 Mar;19(3):313-8. doi: 10.1128/CVI.05619-11. Epub 2012 Jan 4.
PMID: 22219315 [PubMed - indexed for MEDLINE] Free PMC Article
Related citations
27 84.
Pr eventing cancer with va ccines: progress in the global control of cancer.
Kane MA.
Cancer Prev Res (Phila). 2012 Jan;5(1):24-9. doi: 10.1158/1940-6207.CAPR-11-0533.
PMID: 22219163 [PubMed - indexed for MEDLINE]
Related citations
85.
V accine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species.
Colloca S, Barnes E, Folgori A, Ammendola V, Capone S, Cirillo A, Siani L, Naddeo M, Grazioli F, Esposito ML, Ambrosio M, Sparacino A, Bartiromo M, Meola A, Smith K, Kurioka A, O'Hara GA, Ewer KJ, Anagnostou N, Bliss C, Hill AV, Traboni C, Klenerman P, Cortese R, Nicosia A.
Sci Transl Med. 2012 Jan 4;4(115):115ra2. doi: 10.1126/scitranslmed.3002925.
PMID: 22218691 [PubMed - indexed for MEDLINE] Free Article
Related citations
86.
N ovel adenovirus-based va ccines induce broad and sustained T cell responses to HCV in man.
Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A, Meyer J, Huddart R, Smith K, Townsend R, Brown A, Antrobus R, Ammendola V, Naddeo M, O'Hara G, Willberg C, Harrison A, Grazioli F, Esposito ML, Siani L, Traboni C, Oo Y, Adams D, Hill A, Colloca S, Nicosia A, Cortese R, Klenerman P.
Sci Transl Med. 2012 Jan 4;4(115):115ra1. doi: 10.1126/scitranslmed.3003155.
PMID: 22218690 [PubMed - indexed for MEDLINE] Free Article
Related citations
87.
28 C himp virus makes a savvy va ccine vector.
Houghton M.
Sci Transl Med. 2012 Jan 4;4(115):115fs1. doi: 10.1126/scitranslmed.3003526. No abstract available.
PMID: 22218689 [PubMed - indexed for MEDLINE]
Related citations
88.
Pe rceptions of sexual risk compensation following posttrial HIV va ccine uptake among young South Africans.
Macphail CL, Sayles JN, Cunningham W, Newman PA.
Qual Health Res. 2012 May;22(5):668-78. doi: 10.1177/1049732311431944. Epub 2012 Jan 4.
PMID: 22218269 [PubMed - indexed for MEDLINE]
Related citations
89.
V accinations while on thiopurines: some protection is better than none.
Melmed GY.
Am J Gastroenterol. 2012 Jan;107(1):141-2. doi: 10.1038/ajg.2011.320. No abstract available.
PMID: 22218037 [PubMed - indexed for MEDLINE]
Related citations
90.
V accine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys.
Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, Iampietro MJ, SanMiguel A, Seaman MS, Ferrari G, Forthal DN, Ourmanov I, Hirsch VM, Carville A, Mansfield KG, Stablein D, Pau MG, Schuitemaker H, Sadoff JC, Billings EA, Rao M, Robb ML, Kim JH, Marovich MA, Goudsmit J, Michael NL.
29 Nature. 2012 Jan 4;482(7383):89-93. doi: 10.1038/nature10766.
PMID: 22217938 [PubMed - indexed for MEDLINE] Free PMC Article
Related citations
91.
R eceipt of A(H1N1)pdm09 va ccine by prisons and jails - United States, 2009-10 influenza season.
Centers for Disease Control and Prevention (CDC).
MMWR Morb Mortal Wkly Rep. 2012 Jan 6;60(51-52):1737-40. Erratum in: MMWR Morb Mortal Wkly Rep. 2012 Jan 27;61(3):57.
PMID: 22217623 [PubMed - indexed for MEDLINE] Free Article
Related citations
92.
[An infant with meningitis caused by resistant pneumococcus: infection despite va ccination] . van der Meer H, van Zwol A, Spanjaard L, van Furth M.
Ned Tijdschr Geneeskd. 2012;156(1):A3806. Dutch.
PMID: 22217305 [PubMed - indexed for MEDLINE]
Related citations
93.
D ifferentiation of West Nile virus-infected animals from va ccinated animals by competitive ELISA using monoclonal antibodies against non-structural protein 1.
Yeh JY, Chung KM, Song J.
Vector Borne Zoonotic Dis. 2012 May;12(5):380-7. doi: 10.1089/vbz.2011.0796. Epub 2012 Jan 4.
PMID: 22217168 [PubMed - indexed for MEDLINE] 30 Related citations
94.
Acute sleep deprivation has no lasting effects on the human antibody titer response fo llowing a novel influenza A H1N1 virus va ccination.
Benedict C, Brytting M, Markström A, Broman JE, Schiöth HB.
BMC Immunol. 2012 Jan 4;13:1. doi: 10.1186/1471-2172-13-1.
PMID: 22217111 [PubMed - indexed for MEDLINE] Free PMC Article
Related citations
95.
N ational surveillance for human and pet contact with oral rabies va ccine baits, 2001- 2009.
Roess AA, Rea N, Lederman E, Dato V, Chipman R, Slate D, Reynolds MG, Damon IK, Rupprecht CE.
J Am Vet Med Assoc. 2012 Jan 15;240(2):163-8. doi: 10.2460/javma.240.2.163.
PMID: 22217024 [PubMed - indexed for MEDLINE]
Related citations
96.
C ancers that U.S. physicians believe the HPV va ccine prevents: findings from a physician survey, 2009.
Saraiya M, Rosser JI, Cooper CP.
J Womens Health (Larchmt). 2012 Feb;21(2):111-7. doi: 10.1089/jwh.2011.3313. Epub 2012 Jan 4.
PMID: 22216920 [PubMed - indexed for MEDLINE]
Related citations
97.
Effi cacy results of a trial of a herpes simplex va ccine.
31 Belshe RB, Leone PA, Bernstein DI, Wald A, Levin MJ, Stapleton JT, Gorfinkel I, Morrow RL, Ewell MG, Stokes-Riner A, Dubin G, Heineman TC, Schulte JM, Deal CD; Herpevac Trial for Women.
N Engl J Med. 2012 Jan 5;366(1):34-43. doi: 10.1056/NEJMoa1103151.
PMID: 22216840 [PubMed - indexed for MEDLINE] Free PMC Article
Related citations
98.
[ Seasonal influenza va ccination, a campaign just until January 31, 2012].
Debertrand N.
Soins. 2011 Nov;(760):8. French. No abstract available.
PMID: 22216631 [PubMed - indexed for MEDLINE]
Related citations
99.
S ingle dose novel Salmonella va ccine enhances resistance against visceralizing L. major and L. donovani infection in susceptible BALB/c mice.
Schroeder J, Brown N, Kaye P, Aebischer T.
PLoS Negl Trop Dis. 2011 Dec;5(12):e1406. doi: 10.1371/journal.pntd.0001406. Epub 2011 Dec 27.
PMID: 22216363 [PubMed - indexed for MEDLINE] Free PMC Article
Related citations
100.
A ttitudes toward and uptake of H1N1 va ccine among health care workers during the 2009 H1N1 pandemic.
Henriksen Hellyer JM, DeVries AS, Jenkins SM, Lackore KA, James KM, Ziegenfuss JY, Poland GA, Tilburt JC.
PLoS One. 2011;6(12):e29478. doi: 10.1371/journal.pone.0029478. Epub 2011 Dec 22. 32 PMID: 22216290 [PubMed - indexed for MEDLINE] Free PMC Article
Related citations
101.
I nfluenza va ccination for immunocompromised patients: systematic review and meta- analysis from a public health policy perspective.
Beck CR, McKenzie BC, Hashim AB, Harris RC, Zanuzdana A, Agboado G, Orton E, Béchard-Evans L, Morgan G, Stevenson C, Weston R, Mukaigawara M, Enstone J, Augustine G, Butt M, Kim S, Puleston R, Dabke G, Howard R, O'Boyle J, O'Brien M, Ahyow L, Denness H, Farmer S, Figureroa J, Fisher P, Greaves F, Haroon M, Haroon S, Hird C, Isba R, Ishola DA, Kerac M, Parish V, Roberts J, Rosser J, Theaker S, Wallace D, Wigglesworth N, Lingard L, Vinogradova Y, Horiuchi H, Peñalver J, Nguyen-Van-Tam JS.
PLoS One. 2011;6(12):e29249. doi: 10.1371/journal.pone.0029249. Epub 2011 Dec 22. Review.
PMID: 22216224 [PubMed - indexed for MEDLINE] Free PMC Article
Related citations
102.
No evidence of murine leukemia virus-related viruses in live attenuated human va ccines.
Switzer WM, Zheng H, Simmons G, Zhou Y, Tang S, Shankar A, Kapusinszky B, Delwart EL, Heneine W.
PLoS One. 2011;6(12):e29223. doi: 10.1371/journal.pone.0029223. Epub 2011 Dec 22.
PMID: 22216219 [PubMed - indexed for MEDLINE] Free PMC Article
Related citations
103.
Pr otection in macaques immunized with HIV-1 candidate va ccines can be predicted using the kinetics of their neutralizing antibodies.
Davis D, Koornstra W, Mortier D, Fagrouch Z, Verschoor EJ, Heeney JL, Bogers WM.
33 PLoS One. 2011;6(12):e28974. doi: 10.1371/journal.pone.0028974. Epub 2011 Dec 28.
PMID: 22216149 [PubMed - indexed for MEDLINE] Free PMC Article
Related citations
104.
A ssessment of the variability in influenza A(H1N1) va ccine effectiveness estimates dependent on outcome and methodological approach.
Kavanagh K, Robertson C, McMenamin J.
PLoS One. 2011;6(12):e28743. doi: 10.1371/journal.pone.0028743. Epub 2011 Dec 21.
PMID: 22216108 [PubMed - indexed for MEDLINE] Free PMC Article
Related citations
105.
Adjuvant effect of ginsenoside-based nanoparticles (ginsomes) on the recombinant va ccine against Eimeria tenella in chickens.
Zhang DF, Xu H, Sun BB, Li JQ, Zhou QJ, Zhang HL, Du AF.
Parasitol Res. 2012 Jun;110(6):2445-53. doi: 10.1007/s00436-011-2784-7. Epub 2012 Jan 4.
PMID: 22215190 [PubMed - indexed for MEDLINE]
Related citations
106.
T he determinants of 2009 pandemic A/H1N1 influenza va ccination: a systematic review.
Brien S, Kwong JC, Buckeridge DL.
Vaccine. 2012 Feb 8;30(7):1255-64. doi: 10.1016/j.vaccine.2011.12.089. Epub 2011 Dec 31. Review.
PMID: 34 22214889 [PubMed - in process]
Related citations
107.
D evelopment of a novel in-water va ccination protocol for DNA adenine methylase d eficient Salmonella enterica serovar Typhimurium va ccine in adult sheep.
Mohler VL, Heithoff DM, Mahan MJ, Hornitzky MA, Thomson PC, House JK.
Vaccine. 2012 Feb 14;30(8):1481-91. doi: 10.1016/j.vaccine.2011.12.079. Epub 2011 Dec 31.
PMID: 22214887 [PubMed - indexed for MEDLINE]
Related citations
108.
R otavirus va ccine series completion and adherence to va ccination schedules among infants in managed care in the United States.
Krishnarajah G, Davis EJ, Fan Y, Standaert BA, Buikema AR.
Vaccine. 2012 May 21;30(24):3717-22. doi: 10.1016/j.vaccine.2011.12.077. Epub 2011 Dec 31.
PMID: 22214886 [PubMed - indexed for MEDLINE]
Related citations
109.
Cross-presentation and genome-wide screening reveal candidate T cells antigens for a h erpes simplex virus type 1 va ccine.
Jing L, Haas J, Chong TM, Bruckner JJ, Dann GC, Dong L, Marshak JO, McClurkan CL, Yamamoto TN, Bailer SM, Laing KJ, Wald A, Verjans GM, Koelle DM.
J Clin Invest. 2012 Feb 1;122(2):654-73. doi: 10.1172/JCI60556. Epub 2012 Jan 3. Erratum in: J Clin Invest. 2012 Aug 1;122(8):3024.
PMID: 22214845 [PubMed - indexed for MEDLINE] Free PMC Article
Related citations 35 110.
Elderly-onset neuromyelitis optica which developed after the diagnosis of prostate adenocarcinoma and relapsed after a 23-valent pneumococcal polysaccharide va ccination.
Kitazawa Y, Warabi Y, Bandoh M, Takahashi T, Matsubara S.
Intern Med. 2012;51(1):103-7. Epub 2012 Jan 1.
PMID: 22214633 [PubMed - indexed for MEDLINE] Free Article
Related citations
111.
Eva luation of heterologous vaginal SHIV SF162p4 infection following va ccination with a polyvalent Clade B virus-like particle va ccine.
McBurney SP, Landucci G, Forthal DN, Ross TM.
AIDS Res Hum Retroviruses. 2012 Sep;28(9):1063-72. doi: 10.1089/AID.2011.0351. Epub 2012 Mar 21.
PMID: 22214267 [PubMed - indexed for MEDLINE]
Related citations
112.
[ Peptide va ccine treatment for colorectal cancer].
Okuno K.
Nihon Rinsho. 2011 Apr;69 Suppl 3:574-8. Review. Japanese. No abstract available.
PMID: 22214026 [PubMed - indexed for MEDLINE]
Related citations
A MEDEO - Vaccines Publicaciones ( 07 - 01 - 2013): 22 artículos nuevos.
36 Vacunas meningococo (Neisseria meningitidis)
17. KAAIJK P, van Straaten I, van de Waterbeemd B, Boot EP, et al. Preclinical safety and immunogenicity evaluation of a nonavalent PorA native outer membrane vesicle vaccine against serogroup B meningococcal disease. Vaccine. 2012 Dec 27. pii: S0264-410X(12)01815. PubMed: www.amedeo.com/p2.php?id=23273968&s=vac&pm=badc2a9eebb0fad ABSTRACT available Share: http://m.amedeo.com/23273968
18. Priorities for research on meningocccal disease and the impact of serogroup A vaccination in the African meningitis belt. Vaccine. 2012 Dec 27. pii: S0264-410X(12)01820. PubMed: www.amedeo.com/p2.php?id=23273967&s=vac&pm=badc2a9eebb0fad ABSTRACT available Share: http://m.amedeo.com/23273967
Vacunas BCG – ONCO BCG (Mycobacterium bovis)
19. WAECKERLE-MEN Y, Bruffaerts N, Liang Y, Jurion F, et al. Lymph node targeting of BCG vaccines amplifies CD4 and CD8 T-cell responses and protection against Mycobacterium tuberculosis. Vaccine. 2012 Dec 25. pii: S0264-410X(12)01818. PubMed: www.amedeo.com/p2.php?id=23273509&s=vac&pm=badc2a9eebb0fad ABSTRACT available Share: http://m.amedeo.com/23273509
Vacunas neumococo (Streptococcus pneumoniae)
11. NOVAK D, Lundgren A, Westphal S, Valdimarsson S, et al. Two cases of hemolytic uremic syndrome caused by Streptococcus pneumoniae serotype 3, one being a vaccine failure. Scand J Infect Dis. 2012. PubMed: www.amedeo.com/p2.php?id=23270474&s=vac&pm=badc2a9eebb0fad ABSTRACT available Share: http://m.amedeo.com/23270474
22. BENAVIDES JA, Ovalle OO, Salvador GR, Gray S, et al. Population-based surveillance for invasive pneumococcal disease and pneumonia in infants and young children in Bogota, Colombia. Vaccine. 2012;30:5886-92. PubMed: www.amedeo.com/p2.php?id=22484295&s=vac&pm=badc2a9eebb0fad ABSTRACT available Share: http://m.amedeo.com/22484295
Vacunas, otras
1. NEOGI U, Gupta S, Sahoo PN, Shet A, et al. Genetic characterization of HIV-1 Tat exon 1 from a southern Indian clinical cohort: identification of unique epidemiological signature residues. AIDS Res Hum Retroviruses. 2012. PubMed: www.amedeo.com/p2.php?id=22236201&s=vac&pm=badc2a9eebb0fad ABSTRACT available Share: http://m.amedeo.com/22236201
2. MCKITTRICK N, Frank I, Jacobson JM, White CJ, et al. Improved Immunogenicity With High-Dose Seasonal Influenza Vaccine in HIV-Infected
Persons: A Single-Center, Parallel, Randomized Trial. Ann Intern Med. 2013;158:19-26. 37 PubMed: www.amedeo.com/p2.php?id=23277897&s=vac&pm=badc2a9eebb0fad ABSTRACT available Share: http://m.amedeo.com/23277897
3. ARNHEIM-DAHLSTROM L, Hallgren J, Weibull CE, Sparen P, et al. Risk of presentation to hospital with epileptic seizures after vaccination with monovalent AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine (Pandemrix): self controlled case series study. BMJ. 2012;345:e7594. PubMed: www.amedeo.com/p2.php?id=23274350&s=vac&pm=badc2a9eebb0fad ABSTRACT available Share: http://m.amedeo.com/23274350
4. CHATTERJEE P. Advertising watchdog bans "misleading" commercial on rotavirus vaccination. BMJ. 2012;345:e8682. PubMed: www.amedeo.com/p2.php?id=23271746&s=vac&pm=badc2a9eebb0fad
Share: http://m.amedeo.com/23271746
5. PAUL Y. IPV for OPV primed children. Indian Pediatr. 2012;49:423. PubMed: www.amedeo.com/p2.php?id=22700678&s=vac&pm=badc2a9eebb0fad
Share: http://m.amedeo.com/22700678
6. HOLMSTROM F, Pasetto A, Nahr V, Brass A, et al. A Synthetic Codon-Optimized Hepatitis C Virus Nonstructural 5A DNA Vaccine Primes Polyfunctional CD8+ T Cell Responses in Wild-Type and NS5A-Transgenic Mice. J Immunol. 2013. PubMed: www.amedeo.com/p2.php?id=23284053&s=vac&pm=badc2a9eebb0fad ABSTRACT available Share: http://m.amedeo.com/23284053
7. CAPITINI CM, Nasholm NM, Duncan BB, Guimond M, et al. Graft-versus-Host Disease Impairs Vaccine Responses through Decreased CD4+ and CD8+ T Cell Proliferation and Increased Perforin-Mediated CD8+ T Cell Apoptosis. J Immunol. 2012. PubMed: www.amedeo.com/p2.php?id=23275602&s=vac&pm=badc2a9eebb0fad ABSTRACT available Share: http://m.amedeo.com/23275602
8. ROCKMAN S, Brown LE, Barr IG, Gilbertson B, et al. Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza in ferrets immunised with seasonal influenza vaccine. J Virol. 2013. PubMed: www.amedeo.com/p2.php?id=23283953&s=vac&pm=badc2a9eebb0fad ABSTRACT available Share: http://m.amedeo.com/23283953
9. Progress toward poliomyelitis eradication - Nigeria, January 2011-September 2012.
38 MMWR Morb Mortal Wkly Rep. 2012;61:899-904. PubMed: www.amedeo.com/p2.php?id=23134973&s=vac&pm=badc2a9eebb0fad ABSTRACT available Share: http://m.amedeo.com/23134973
10. HEIKKINEN T, Block SL, Toback SL, Wu X, et al. Effectiveness of Intranasal Live Attenuated Influenza Vaccine against All-cause Acute Otitis Media in Children. Pediatr Infect Dis J. 2012. PubMed: www.amedeo.com/p2.php?id=23271441&s=vac&pm=badc2a9eebb0fad ABSTRACT available Share: http://m.amedeo.com/23271441
11. NOVAK D, Lundgren A, Westphal S, Valdimarsson S, et al. Two cases of hemolytic uremic syndrome caused by Streptococcus pneumoniae serotype 3, one being a vaccine failure. Scand J Infect Dis. 2012. PubMed: www.amedeo.com/p2.php?id=23270474&s=vac&pm=badc2a9eebb0fad ABSTRACT available Share: http://m.amedeo.com/23270474
12. JIMENEZ HR, Hallit RR, Debari VA, Slim J, et al. Hepatitis A vaccine response in HIV-infected patients: Are TWINRIX((R)) and HAVRIX((R)) interchangeable? Vaccine. 2012 Dec 28. pii: S0264-410X(12)01830. PubMed: www.amedeo.com/p2.php?id=23277097&s=vac&pm=badc2a9eebb0fad ABSTRACT available Share: http://m.amedeo.com/23277097
13. GALEOTTI M, Romano N, Volpatti D, Bulfon C, et al. Innovative vaccination protocol against vibriosis in Dicentrarchus labrax (L.) juveniles: Improvement of immune parameters and protection to challenge. Vaccine. 2012 Dec 28. pii: S0264-410X(12)01826. PubMed: www.amedeo.com/p2.php?id=23277096&s=vac&pm=badc2a9eebb0fad ABSTRACT available Share: http://m.amedeo.com/23277096
14. BOWYER HL, Marlow LA, Hibbitts S, Pollock KG, et al. Knowledge and awareness of HPV and the HPV vaccine among young women in the first routinely vaccinated cohort in England. Vaccine. 2012 Dec 28. pii: S0264-410X(12)01823. PubMed: www.amedeo.com/p2.php?id=23277094&s=vac&pm=badc2a9eebb0fad ABSTRACT available Share: http://m.amedeo.com/23277094
15. SA E SILVA M, Ellis A, Karaca K, Minke J, et al. Domestic goose as a model for West Nile virus vaccine efficacy. Vaccine. 2012 Dec 28. pii: S0264-410X(12)01829. PubMed: www.amedeo.com/p2.php?id=23277093&s=vac&pm=badc2a9eebb0fad ABSTRACT available Share: http://m.amedeo.com/23277093
39 16. LOPES VB, Hassing RJ, de Vries-Sluijs TE, El Barzouhi A, et al. Long-term response rates of successful hepatitis B vaccination in HIV-infected patients. Vaccine. 2012 Dec 27. pii: S0264-410X(12)01832. PubMed: www.amedeo.com/p2.php?id=23273969&s=vac&pm=badc2a9eebb0fad ABSTRACT available Share: http://m.amedeo.com/23273969
17. KAAIJK P, van Straaten I, van de Waterbeemd B, Boot EP, et al. Preclinical safety and immunogenicity evaluation of a nonavalent PorA native outer membrane vesicle vaccine against serogroup B meningococcal disease. Vaccine. 2012 Dec 27. pii: S0264-410X(12)01815. PubMed: www.amedeo.com/p2.php?id=23273968&s=vac&pm=badc2a9eebb0fad ABSTRACT available Share: http://m.amedeo.com/23273968
18. Priorities for research on meningocccal disease and the impact of serogroup A vaccination in the African meningitis belt. Vaccine. 2012 Dec 27. pii: S0264-410X(12)01820. PubMed: www.amedeo.com/p2.php?id=23273967&s=vac&pm=badc2a9eebb0fad ABSTRACT available Share: http://m.amedeo.com/23273967
19. WAECKERLE-MEN Y, Bruffaerts N, Liang Y, Jurion F, et al. Lymph node targeting of BCG vaccines amplifies CD4 and CD8 T-cell responses and protection against Mycobacterium tuberculosis. Vaccine. 2012 Dec 25. pii: S0264-410X(12)01818. PubMed: www.amedeo.com/p2.php?id=23273509&s=vac&pm=badc2a9eebb0fad ABSTRACT available Share: http://m.amedeo.com/23273509
20. TAFAGHODI M, Saluja V, Kersten GF, Kraan H, et al. Hepatitis B surface antigen nanoparticles coated with chitosan and trimethyl chitosan: Impact of formulation on physicochemical and immunological characteristics. Vaccine. 2012. PubMed: www.amedeo.com/p2.php?id=22749834&s=vac&pm=badc2a9eebb0fad ABSTRACT available Share: http://m.amedeo.com/22749834
21. SAZZAD HM, Rainey JJ, Mach O, Sutter R, et al. The feasibility of identifying children with primary immunodeficiency disorders: preparation for the polio post-eradication era in Bangladesh. Vaccine. 2012;30:5396-400. PubMed: www.amedeo.com/p2.php?id=22728220&s=vac&pm=badc2a9eebb0fad ABSTRACT available Share: http://m.amedeo.com/22728220
22. BENAVIDES JA, Ovalle OO, Salvador GR, Gray S, et al. Population-based surveillance for invasive pneumococcal disease and pneumonia in infants and young children in Bogota, Colombia. Vaccine. 2012;30:5886-92.
40 PubMed: www.amedeo.com/p2.php?id=22484295&s=vac&pm=badc2a9eebb0fad ABSTRACT available Share: http://m.amedeo.com/22484295
PATENTES
United States Patent and Trademark Office (USPTO)
Estrategia de búsqueda “vaccine” en título y abstract
(ABST/vaccine AND ISD/20130101->20130111): 9 patentes recuperadas.
Vacunas, otras
PAT. NO. Title
1 8,350,018 Polynucleotides of Haemophilus parasuis and its use
2 8,349,558 Detection of individual T-cell reaction patterns against tumor- associated antigens (TAA) in tumor patients as a basis for the individual therapeutic vaccination of patients
3 8,349,315 Use of Lactobacillus casei for increasing the protection provided by the influenza vaccine
4 8,343,718 Strain of SARS-associated coronavirus and applications thereof
5 8,343,512 Treatment of allergic conditions using a composition containing synthetic adjuvant
6 8,343,510 Protective proteins of S. agalactiae, combinations thereof and methods of using the same
7 8,343,507 Protein from Photobacterium damselae and use thereof
8 8,343,505 Subunit vaccine for aquaculture
9 8,343,502 Yeast-based vaccines as immunotherapy
European Patent Office (EPO)
41 Acumulado entre el 1 y el 11 de enero de 2013: 10 patentes recuperadas
Vacunas neumococo (Streptococcus pneumoniae)
10. C OMBINATION V ACCINE FOR STREPTOCOCCUS
Publication info: EP2538971 (A1) 2013-01-02
Vacunas, otras
1. M UCOSAL V ACCINE
Publication info: EP2543387 (A1) 2013-01-09
2. S ACCHARIDE NANOCOMPOSITIONS FOR V ACCINE RELEASE
Publication info: WO2013001124 (A1) 2013-01-03
3. C ANINE CORONAVIRUS V ACCINE
Publication info: WO2013000905 (A1) 2013-01-03
4. COMPOSITION OF TUMOR-ASSOCIATED PEPTIDES AND RELATED ANTI-CANCER V ACCINE FOR THE TREATMENT OF GLIOBLASTOMA (GBM) AND OTHER CANCERS
Publication info: US2013004456 (A1) 2013-01-03
5. C ontinuous monitoring methods in va ccine production
Publication info: US2013006563 (A1) 2013-01-03
6. I NACTIVATING PATHOGENS WITH OXIDIZING AGENTS FOR V ACCINE PRODUCTION
Publication info: US2013004525 (A1) 2013-01-03
7. V ACCINE
Publication info: US2013004510 (A1) 2013-01-03
8. V ACCINE COMPOSITION
Publication info: US2013004530 (A1) 2013-01-03
9. C ANCER V ACCINE
Publication info: EP2539368 (A1) 2013-01-02
10. C OMBINATION V ACCINE FOR STREPTOCOCCUS
42 Publication info: EP2538971 (A1) 2013-01-02
TABLAS DE CONTENIDO
Tabla de Contenidos. Volume 31, Issue 2, Pages 279 - 438 (2 January, 2012)
1. Editorial Board/Aims and Scope
Pages CO2
Meeting reports
2. The first national adult immunization summit 2012: Implementing change through action
Pages 279-284 Angela K. Shen, Carolyn B. Bridges, Litjen Tan
3. WHO position paper on hepatitis A vaccines: June 2012—Recommendations
Pages 285-286
Brief report
4. Correlates of seasonal flu vaccination among U.S. home health aides
Pages 287-290 Alberto Juan Caban-Martinez, Anna Arlinghaus, Silje E. Reme
Short communications
5. Assessment of functional antibacterial opsonophagocytic antibodies elicited by 13- valent pneumococcal conjugate vaccine administered concomitantly with trivalent influenza vaccine in a randomized clinical trial in adults aged ≥65 years
Pages 291-294 Tino F. Schwarz, Beate Schmoele-Thoma
43 Highlights
► PCV13 was coadministered with TIV or given separately 1 month after TIV. ► OPA responses were lower after coadministration compared to separate administration. ► Noninferiority criteria were met for most serotypes after vaccine coadministration. ► The proportion of OPA responders was similar across the two vaccine groups. ► The concomitant use of PCV13 and TIV should be guided by clinical circumstances.
6. Varicella infection in infants less than 12 months
Pages 295-296 Sally Campbell, Nigel W. Crawford
Highlights
► This manuscript highlights the significant morbidity that can occur with varicella infections. ► It highlights the issue surrounding vaccination for children
Review
7. T cell vaccinology: Exploring the known unknowns Review Article
Pages 297-305 Matt A. Burchill, Beth A. Tamburini, Nathan D. Pennock, Jason T. White, Jonathan S. Kurche, Ross M. Kedl
Highlights
► Subunit vaccines are safer than live attenuated vaccines but poorly generate cellular immunity. ► A subunit vaccine that can elicit potent cellular immunity is an unmet need in vaccine development. ► We describe six areas of inquiry in which further investigation is needed for vaccine development.
Regular papers
8. The role of non-viral antigens in the cotton rat model of respiratory syncytial virus vaccine-enhanced disease Original Research Article
Pages 306-312 Christine A. Shaw, Jean-Rene Galarneau, Kathryn E. Bowenkamp, Kurt A. Swanson, Gene A. Palmer, Giuseppe Palladino, Judit E. Markovits, Nicholas M. Valiante, Philip R. Dormitzer, Gillis R. Otten
Highlights
► Investigated mechanism of FI-RSV-mediated vaccine-enhanced disease in cotton rats. ► Non-viral antigens in vaccine and challenge materials drive lung pathology. ► Clear association between alveolitis and cellular response to non-viral antigens. ► RSV antigens enhance alveolitis severity and cellular response to non-viral antigens. ► RSV and FI-RSV induce T cells specific for 3 peptide epitopes in RSV F.
44 9. A cinetobacter baumannii rOmpA vaccine dose alters immune polarization and immunodominant epitopes Original Research Article
Pages 313-318 Lin Lin, Brandon Tan, Paul Pantapalangkoor, Tiffany Ho, Andrea M. Hujer, Magdalena A. Taracila, Robert A. Bonomo, Brad Spellberg
Highlights
► Higher doses of the rOmpA anti-Acinetobacter baumanniivaccine induced higher vaccine titers. ► Higher dose of the rOmpA vaccine induced more polarized Type 2 immune response. ► Distinct rOmpA peptides preferentially induced IFN-γ or IL-4T cell responses. ► Higher vaccine dose induced epitope spreading for IL-4 producing lymphocytes. ► Higher vaccine dose induced epitope restriction for IFN-γ producing lymphocytes.
10. Adsorption of recombinant poxvirus L1-protein to aluminum hydroxide/CpG vaccine adjuvants enhances immune responses and protection of mice from vaccinia virus challenge Original Research Article
Pages 319-326 Yuhong Xiao, Yuhong Zeng, Edward Alexander, Shyam Mehta, Sangeeta B. Joshi, George W. Buchman, David B. Volkin, C. Russell Middaugh, Stuart N. Isaacs
Highlights
► Biophysical characterization of the orthopoxvirus L1 vaccine antigen is presented. ► L1-protein adsorbed to Alhydrogel generated better IgG responses than non- adsorbed. ► Addition of CpG to Alhydrogel significantly enhances the anti-L1 antibody responses. ► L1 adsorbed to Alhydrogel resulted in better protection from vaccinia challenge. ► Vaccine formulation design is key to maximize vaccine immunogenicity and protection.
11. Safety and immunogenicity of the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine candidate in adults Original Research Article
Pages 327-333 Thierry Kamtchoua, Monica Bologa, Robert Hopfer, David Neveu, Branda Hu, Xiaohua Sheng, Nicolas Corde, Catherine Pouzet, Gloria Zimmermann, Sanjay Gurunathan
Highlights
► A pneumococcal PlyD1 vaccine candidate was safe in adults. ► The PlyD1 vaccine candidate was immunogenic at 10, 25, and 50μg. ► PlyD1 vaccination induced toxin- neutralizing antibodies.
12. Y ersinia enterocolitica ghost with m sbB mutation provides protection and reduces proinflammatory cytokines in mice Original Research Article
Pages 334-340 Kun Cai, Yong Zhang, Baoyu Yang, Shiyun Chen
Highlights
►Yersinia enterocoliticaghost withmsbBmutation was constructed. ► First to develop bacterial ghosts against infection ofYersiniaspecies. ►msbBgene mutation reduces proinflammatory cytokines in mice.
45 13. Control of viral hepatitis infection in Africa: Are we dreaming? Original Research Article
Pages 341-346 Richard Mihigo, Deo Nshimirimana, Andrew Hall, Michael Kew, Steven Wiersma, C. John Clements
Highlights
► Five different types of viral hepatitis cause a huge burden of disease in Africa. ► Control strategies for each virus overlap. ► Control should start with the common strategies rather than with each disease. ► The impact of these efforts on mortality and morbidity will be significant. ► This will involve multiple strategies that will vary somewhat according location.
14. I mmunogenicity and protective efficacy of recombinant H aemophilus parasuis SH0165 putative outer membrane proteins Original Research Article
Pages 347-353 Shulin Fu, Minmin Zhang, Juan Xu, Jiwen Ou, Yan Wang, Huazhen Liu, Jinlin Liu, Huanchun Chen, Weicheng Bei
Highlights
► The 10 putative OMPs were cloned, expressed and purified as HIS fusion proteins. ► The rGAPDH, rOapA, and rHPS-0675 individually could induce good protective in mice. ► Three proteins elicited good immune response in alone or combination in piglets. ► Combination of three proteins offered best protection againstH. parasuisin piglets. ► The rGAPDH, rOapA, and rHPS-0675 can be a promising subunit vaccine candidate.
15. Anti-melanoma vaccinal capacity of CD11c-positive and -negative cell populations present in GM-CSF cultures derived from murine bone marrow precursors Original Research Article
Pages 354-361 Sabrina Campisano, Soledad Mac Keon, Silvina Gazzaniga, María Sol Ruiz, Martín Dodes Traian, José Mordoh, Rosa Wainstok
Highlights
► The population of DC obtained for vaccination, presents about 60% of CD11c+ DC. ► Only the heterogeneous vaccine (DC/ApoNec) was capable to induce protection. ► This protection seemed to be independent of the vaccine ability's to secrete IL-12. ► CD11c+ DC cells are not the only responsible for the protection achieved.
16. Sustained high influenza vaccination rates and decreased safety concerns among pregnant women during the 2010–2011 influenza season Original Research Article
Pages 362-366 M. Drees, B. Tambourelli, A. Denstman, W. Zhang, R. Zent, P. McGraw, D.B. Ehrenthal
Highlights
► Influenza vaccination rates in pregnancy were sustained in 2010–11 vs. 2009–10. ► Fewer pregnant women were vaccinated by their obstetrical provider in 2010–11. ► Twice as many women reported that their provider did not mention flu vaccination.
46 ► Vaccine safety concerns were much less prominent in 2010–11.
17. DNA vaccine encoding the major virulence factors of Shiga toxin type 2e (Stx2e)- e xpressing E scherichia coli induces protection in mice Original Research Article
Pages 367-372 Wenkai Ren, Rui Yu, Gang Liu, Nengzhang Li, Yuanyi Peng, Miaomiao Wu, Yulong Yin, Yinghui Li, Andrew A. Fatufe, Teijun Li
Highlights
► SLT-IIeB and FedF are the major virulence factors of Shiga-toxigenicEscherichia coli.► SLT-IIeB and FedF were cloned to a pcDNA6.0 plasmid to develop a novel DNA vaccine. ► Co-immunization with pcDNA-SLT-IIeB and pcDNA-FedF is efficient to protect the mice from a subsequent challenge.
18. A full-length recombinant P lasmodium falciparum PfRH5 protein induces inhibitory a ntibodies that are effective across common P fRH5 genetic variants Original Research Article
Pages 373-379 Leyla Y. Bustamante, S. Josefin Bartholdson, Cecile Crosnier, Marta G. Campos, Madushi Wanaguru, Chea Nguon, Dominic P. Kwiatkowski, Gavin J. Wright, Julian C. Rayner
Highlights
► PfRH5 is essential forPlasmodium falciparumerythrocyte invasion. ► Antibodies raised against full-length functional PfRH5 potently blocked invasion. ► Five commonPfRH5polymorphisms were identified across 290 clinical isolates. ► Antibodies raised against one variant inhibited all other common PfRH5 variants. ► Correctly folded recombinant PfRH5 is a strongP. falciparumvaccine candidate.
19. Comparative cost models of a liquid nitrogen vapor phase (LNVP) cold chain- distributed cryopreserved malaria vaccine vs. a conventional vaccine Original Research Article
Pages 380-386 Cristina Reyes Garcia, Fatuma Manzi, Fabrizio Tediosi, Stephen L. Hoffman, Eric R. James
Highlights
► A liquid nitrogen vapor phase (LNVP) cold chain model is described. ► LNVP distribution costs for a cryopreserved malaria vaccine are presented. ► Costs are compared to conventional 2–8°C cold chain vaccine distribution. ► Capital and recurrent costs, and costs for each level and each component are given. ► Overall 5- year costs for the LNVP and 2–8°C cold chain models were very similar.
20. Differences of IgG antibody avidity after an acellular pertussis (aP) booster in adolescents after a whole cell (wcP) or aP primary vaccination Original Research Article
Pages 387-393 M. Prelog, G. Almanzar, N. Rieber, B. Ottensmeier, M. Zlamy, J. Liese
47 Highlights
► Increased IgG-anti-pertussis avidity after adolescent acellular pertussis vaccination. ► Less participants with avidity>40% after previous whole cell pertussis vaccine. ► Correlation between IgG-anti-pertussis avidity and antibody concentration. ► Correlation between IgG-anti-pertussis avidities before and after booster vaccination. ► Avidity as surrogate marker for pertussis-specific long-term immunity.
Regular papers
21. Prevalence, incidence and persistence of genital HPV infections in a large cohort of sexually active young women in the Netherlands Original Research Article
Pages 394-401 M. Mollers, J. Boot Hein, J. Vriend Henrike, J. King Audrey, V.F. van den Broek Ingrid, E.A.M. van Bergen Jan, A.T.P. Brink Antoinette, F.G. Wolffs Petra, J.P.A. Hoebe Christian, J.L.M. Meijer Chris, A.B. van der Sande Marianne, E. de Melker Hester
Highlights
► HPV prevalence (54%), incidence (45%) and persistence (34%) is high. ► Risk factors for HPV persistent and incident infections are different. ► There is an age- dependent increase within this age range for persistent infections but not for incident infections. ► Knowledge on type-specific HPV infections pre-vaccination is essential for monitoring the HPV vaccine.
Regular papers
22. H ow cost effective is universal varicella vaccination in developing countries? A case- study from Colombia Original Research Article
Pages 402-409 Angel Paternina-Caicedo, Fernando De la Hoz-Restrepo, Oscar Gamboa-Garay, Carlos Castañeda-Orjuela, Martha Velandia-González, Nelson Alvis-Guzmán
Highlights
► This study models the impact of varicella vaccination in the Colombian population. ► Mass vaccination against varicella is cost-effective in Colombia from the third-payer perspective. ► Uncertainty of varicella vaccine impact on Herpes-zoster may change cost effectiveness results. ► Developing countries similar to Colombia with high varicella case-fatality rates may benefit from results of our study.
23. Factors affecting repeated influenza vaccination among older people in Taiwan Original Research Article
Pages 410-416 Yu-Chia Chang, Nicole Huang, Long-Sheng Chen, Shang-Wei Hsu, Yiing-Jenq Chou
Highlights
48 ► This study identifies determinants that influence the regular uptake of annual influenza vaccination. ► We use a nationally representative database linked to 2 unique data sets. ► The repeated influenza vaccination rates in our sample were far from optimal. ► Factors identified in this analysis may be further used for improving influenza vaccination programs.
24. Chimeric hepatitis E virus-like particle as a carrier for oral-delivery Original Research Article
Pages 417-424 Pitchanee Jariyapong, Li Xing, Nienke E. van Houten, Tian-Cheng Li, Wattana Weerachatyanukul, Benjamin Hsieh, Carlos G. Moscoso, Chun-Chieh Chen, Masahiro Niikura, R. Holland Cheng
Highlights
► Sequence insertion at antigenic domain of HEV-VLP does not interfere with icosahedral assembly. ► Sequence insertion induces conformational changes at HEV antigenic domain leading to deterioration in antibody-binding. ► Sequence insertion introduces a trypsin cleavage site in the recombinant HEV capsid protein. ► The chimeric VLP remains intact after trypsin cleavage.
25. Antigenic analysis of divergent genotypes human Enterovirus 71 viruses by a panel of neutralizing monoclonal antibodies: Current genotyping of EV71 does not reflect their antigenicity Original Research Article
Pages 425-430 Yixin Chen, Chuan Li, Delei He, Tong Cheng, Shengxiang Ge, James Wai-Kuo Shih, Qinjian Zhao, Pei-Jer Chen, Jun Zhang, Ningshao Xia
Highlights
► To know the difference between antigenicity and genotype of EV71 clinical isolates. ► MAb panel was used to group EV71 isolates based on its reactive profile. ► One class of mAbs which can neutralize all the EV71 isolates was identified. ► We found that current genotyping of EV71 does not reflect their antigenicity. ► This panel of neutralizing mAbs is useful to the selection of EV71 vaccine strain.
Vaccine Safety and Methods
26. Confounder adjustment in vaccine safety studies: Comparing three offset terms for case-centered approach Original Research Article
Pages 431-435 Lei Qian, Hung Fu Tseng, Lina S. Sy, Steven J. Jacobsen
Highlights
► Case-centered approach can adjust for seasonal confounders through an offset term. ► We conduct simulations to compare the performance of three offset terms. ► The model-based offset resulted in best estimate of relative risk. ► A guideline of using the three offset terms is given.
49 Corrigendum
27. Corrigendum to “Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: Results of a randomised single heterologous booster dose study at 15 months” [Vaccine 29 (2011) 6408–6418]
Pages 436-437 George Risi, Louise Frenette, Joanne M. Langley, Ping Li, Dennis Riff, Eric Sheldon, David W. Vaughn, Louis Fries
Tabla de Contenidos. Volume 31, Issue 3, Pages 439 566 (7 January, 2012)
1. Editorial Board/Aims and Scope
Pages CO2
Letters to the Editor
2. Reply to: Economic evaluation of second generation pneumococcal conjugate vaccines in Norway
Pages 439-441 Raymond Farkouh, Rogier Klok, Craig Roberts, Asbjørn Mack, David Strutton
3. Response to “Reply to: Economic evaluation of second generation pneumococcal conjugate vaccines in Norway”
Pages 442-443 Bjarne Robberstad, Per E. Akselsen, Kari J. Kværner, Aud K.H. Berstad
Brief report
4. Antibody persistence of two pentavalent DTwP–HB–Hib vaccines to the age of 15–18 months, and response to the booster dose of quadrivalent DTwP–Hib vaccine
Pages 444-447 Hitt Sharma, Sangeeta Yadav, Sanjay Lalwani, Subhash Kapre, Suresh Jadhav, Sameer Parekh, Sonali Palkar, Satish Ravetkar, Sunil Bahl, Rakesh Kumar, Sunil Shewale
50 Highlights
► Pentavac®vaccine demonstrated an excellent and long-lasting immune response. ► Quadrovax®vaccine induces good anamnestic response to all vaccine components. ► Quadrovax vaccine was well tolerated by all vaccinees. ► No serious adverse event was reported in either group. ► Pentavac is inexpensive and is a good alternative to other costlier similar vaccines.
Short communication
5. A ntibody persistence and the effect of a booster dose given 5, 10 or 15 ye ars after vaccinating preadolescents with a recombinant hepatitis B vaccine
Pages 448-451 Vladimir Gilca, Gaston De Serres, Nicole Boulianne, Donald Murphy, Philippe De Wals, Manale Ouakki, Gisele Trudeau, Richard Massé, Marc Dionne
Highlights
► Persistence of antibody and the effect of a booster dose were monitored. ► Anti-HBs persist for at least 15years post-primary vaccination. ► Excellent immune memory was observed in virtually all vaccines. ► Challenge doses induced long-lasting high anti-HBs titres. ► The results indicate no need in booster doses for at least 15years post- vaccination.
Reviews
6. Immune responses and protection in children in developing countries induced by oral vaccines Review Article
Pages 452-460 Firdausi Qadri, Taufiqur Rahman Bhuiyan, David A. Sack, Ann-Mari Svennerholm
Highlights
► Children in developing countries need different dosage/regimes of oral vaccines. ► Ty21a vaccine induced serum and mucosal B and T-cell responses were observed. ► Administration of rotavirus and OPV may lower the response to rotavirus vaccine. ► Zinc has positive effect to immune response to Dukoral and pneumococcal vaccine.
7. Immune evasion strategies of flaviviruses Review Article
Pages 461-471 Jing Ye, Bibo Zhu, Zhen F. Fu, Huanchun Chen, Shengbo Cao
Highlights
51 ► Flaviviruses have evolved a variety of strategies to modulate the immune responses of host. ► Mechanisms by which flaviviruses evade the innate and adaptive immunity of the host are summarized based on current studies. ► Flaviviruses limit type I IFN signaling by blocking the host gene expression, thus attenuating innate immunity. ► Flaviviruses also inhibit the antiviral immune response of complement system and NK cells. ► High genetic variability of viral antigens allows viral escape from both humoral and cellular immunity against flaviviruses.
Regular papers
8. Enhancement of HIV-1 DNA vaccine immunogenicity by BCG-PSN, a novel adjuvant Original Research Article
Pages 472-479 Jing Sun, Jue Hou, Dingfeng Li, Yong Liu, Ningzhu Hu, Yanling Hao, Jingjing Fu, Yunzhang Hu, Yiming Shao
Highlights
► We found that BCG-PSN could significantly improve the immunogenicity of DNA vaccine when co-administered with DNA vaccine. ► DNA vaccine co-administrated with BCG-PSN could decrease 10-fold dose of vaccine requirement. ► Our results demonstrate that BCG-PSN can activate TLR signaling pathways and induce Th1-type cytokines secretion. ► Our results may provide valuable information for designing an effective HIV-1 DNA vaccine immunization strategy. 9. The potential economic value of a cutaneous leishmaniasis vaccine in seven endemic countries in the Americas Original Research Article
Pages 480-486 Kristina M. Bacon, Peter J. Hotez, Stephanie D. Kruchten, Shaden Kamhawi, Maria Elena Bottazzi, Jesus G. Valenzuela, Bruce Y. Lee
Highlights
► We constructed and utilized a computer simulation model to evaluate the economic value of a CL vaccine. ► Modest protection duration and efficacy are required for CL vaccination to cost less than treatment. ► A preventative CL vaccine could save costs at moderate levels of infection risk. 10. A PCV2 vaccine based on genotype 2b is more effective than a 2a-based vaccine to protect against PCV2b or combined PCV2a/2b viremia in pigs with concurrent PCV2, PRRSV and PPV infection Original Research Article
Pages 487-494 Tanja Opriessnig, Kevin O’Neill, Priscilla F. Gerber, Alessandra M.M.G. de Castro, Luis G. Gimenéz-Lirola, Nathan M. Beach, Lei Zhou, Xiang-Jin Meng, Chong Wang, Patrick G. Halbur
Highlights
52 ► Commercial PCV2 vaccines are based on PCV2a; most field infections are due to PCV2b. ► PCV2 vaccines based on genotypes 2a and 2b were compared. ► PCV2b vaccination was more effective in the experimental pig model. ► PCV2a and PCV2b coinfection resulted in clinical manifest disease. 11. E valuation of 238 antigens of L eptospira borgpetersenii serovar Hardjo for protection against kidney colonisation Original Research Article
Pages 495-499 Gerald L. Murray, Miranda Lo, Dieter M. Bulach, Amporn Srikram, Torsten Seemann, Noelene S. Quinsey, Rasana W. Sermswan, Andy Allen, Ben Adler
12. The impact of maternally derived immunity on influenza A virus transmission in neonatal pig populations Original Research Article
Pages 500-505 Matt Allerson, John Deen, Susan E. Detmer, Marie R. Gramer, Han Soo Joo, Anna Romagosa, Montserrat Torremorell
13. Hepatitis B specific T cell immunity induced by primary vaccination persists independently of the protective serum antibody level Original Research Article
Pages 506-513 Maria Carollo, Raffaella Palazzo, Manuela Bianco, Elisabetta Pandolfi, Paola Chionne, Giorgio Fedele, Alberto Eugenio Tozzi, Rita Carsetti, Luisa Romanò, Clara Maria Ausiello
Highlights
► Concerns about immunogenicity of hepatitis B virus component of Hexavac vaccine. ► T response to establish differences in Hexavac/Infanrix primary vaccinated children. ► Both vaccines are efficient in generating T recall responses 5 years after vaccination. ► Less immunogenic Hexavac induces strong HBsAg recall proliferation/memory subsets. ► Cellular immune and serological responses are important as surrogate of protection. 14. Voluntary reporting of health care personnel seasonal influenza vaccination rates and the impact of universal policies in Illinois hospitals Original Research Article
Pages 514-517 Bonnie Paris, Tracey Arahood, Carl Asche, Gail Amundson
Highlights
► We describe health care personnel seasonal influenza vaccination rates in Illinois hospitals over 3 years. ► Employees vaccinated earlier in the influenza season have greater benefit over time. ► Public reporting may contribute to universal employee vaccination policy adoption. ► Universal policies result in higher vaccination rates than voluntary programs. 15. Influenza vaccination in Turkey: Prevalence of risk groups, current vaccination status, factors influencing vaccine uptake and steps taken to increase vaccination rate Original Research Article
53 Pages 518-523 Meral Akcay Ciblak
Highlights
► This study shows that there are about 27–33 million people in risk groups in Turkey. ► Vaccines are provided to the HCWs free of charge and vaccination charges are reimbursed for the risk groups. ► The vaccination coverage rate is low in all risk groups especially in the elderly. ► Major absticle before the vaccination was disbelief in the vaccine effectiveness. ► A stakeholder network, Grip Paltformu, including MoH was established to combat flu effectively. 16. Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine Original Research Article
Pages 524-532 Gregory M. Glenn, Gale Smith, Louis Fries, Rama Raghunandan, Hanxin Lu, Bin Zhou, D. Nigel Thomas, Somia P. Hickman, Eloi Kpamegan, Sarathi Boddapati, Pedro A. Piedra
Highlights
► This Phase 1 trial evaluated the safety and immunogenicity of an RSV (F) nanoparticle vaccine. ► The vaccine was well-tolerated and no related SAEs were observed. ► Both RSV A and B microneutralizating antibodies were increased in vaccinees versus placebo. ► There was a 7- to 19-fold increase in anti-F IgG and a 7- to 24-fold increase in palivizumab-like antibodies. ► The levels of immunity are similar to those seen in other settings with decreased hospitalizations. 17. Waning immunity to measles in young adults and booster effects of revaccination in secondary school students Original Research Article
Pages 533-537 Hanqing He, En-fu Chen, Qian Li, Zhifang Wang, Rui Yan, Jian Fu, Jinren Pan
Highlights
► The population immunity did not reach the presumed thresholds of measles elimination. ► The significant decay of antibody against measles was found since adolescences. ► Secondary school students can acquire sufficient immunity to measles after revaccination. ► Revaccination program can be conducted effectively and practically in secondary school. 18. Comprehensive evaluation of the adenovirus/alphavirus-replicon chimeric vector-based vaccine rAdV-SFV-E2 against classical swine fever Original Research Article
Pages 538-544 Yuan Sun, Da-Yong Tian, Su Li, Qi-Lin Meng, Bi-Bo Zhao, Yongfeng Li, Dan Li, Li-Jun Ling, Ya-Jin Liao, Hua-Ji Qiu
Highlights
► The chimeric vector-based vaccine rAdV-SFV-E2 was safe for mice, rabbits and pigs.
54 ► Low dose or single immunization with the vaccine provided full protection from CSF. ► Anti-CSFV antibodies or pre-immunization with the vaccine did not affect its efficacy. ► The vaccine administered alone or together with PRV vaccine induced equal protection. 19. TAT-mediated gp96 transduction to APCs enhances gp96-induced antiviral and antitumor T cell responses Original Research Article
Pages 545-552 Bao Zhao, Yanzhong Wang, Yu Zhang, Yang Li, Xiaojun Zhang, Yaxing Xu, Lizhao Chen, Changfei Li, Ying Ju, Songdong Meng
Highlights
► We designed a more efficient approach to improve the adjuvant functions of gp96. ► The cell-penetrating peptide TAT increased gp96 internalization into macrophages. ► TAT-based gp96 delivery increased gp96-induced T cell responses. ► TAT fusion remarkably enhanced gp96-mediated antiviral efficiency. ► TAT fusion significantly enhanced gp96-mediated antitumor activity. 20. Bluetongue virus serotype 8 virus-like particles protect sheep against virulent virus infection as a single or multi-serotype cocktail immunogen Original Research Article
Pages 553-558 Meredith Stewart, Eric Dubois, Corinne Sailleau, Emmanuel Bréard, Cyril Viarouge, Alexandra Desprat, Richard Thiéry, Stéphan Zientara, Polly Roy
Highlights
► Development of Bluetongue virus-like particle (BTV VLP) for serotype 8. ► Assessment of BTV-8 VLPs as protective immunogen in sheep. ► No interference of immunogenicity in sheep vaccinated with VLP-cocktail. ► Multiple VLP vaccine protects sheep against BT disease. 21. Safety and immunogenicity of recombinant Rift Valley fever MP-12 vaccine candidates in sheep Original Research Article
Pages 559-565 John C. Morrill, Richard C. Laughlin, Nandadeva Lokugamage, Roberta Pugh, Elena Sbrana, William J. Weise, L. Garry Adams, Shinji Makino, C.J. Peters
Highlights
► We tested 2 recombinant RVF MP-12 vaccine candidates in 30- to 50-day pregnant ewes. ► No abortions or fetal abnormalities were observed. ► The arMP- 12ΔNSm21/384 candidate was immunogenic and safe in pregnant ewes. ► A dose of 1×103PFU stimulates a PRNT80response comparable to higher doses.
Tabla de Contenidos. Volume 31, Issue 3, Pages 439 566 (7 January, 2012)
55 1. Editorial Board/Aims and Scope
Pages CO2
Letters to the Editor
2. Reply to: Economic evaluation of second generation pneumococcal conjugate vaccines in Norway
Pages 439-441 Raymond Farkouh, Rogier Klok, Craig Roberts, Asbjørn Mack, David Strutton
3. Response to “Reply to: Economic evaluation of second generation pneumococcal conjugate vaccines in Norway”
Pages 442-443 Bjarne Robberstad, Per E. Akselsen, Kari J. Kværner, Aud K.H. Berstad
Brief report
4. Antibody persistence of two pentavalent DTwP–HB–Hib vaccines to the age of 15–18 months, and response to the booster dose of quadrivalent DTwP–Hib vaccine
Pages 444-447 Hitt Sharma, Sangeeta Yadav, Sanjay Lalwani, Subhash Kapre, Suresh Jadhav, Sameer Parekh, Sonali Palkar, Satish Ravetkar, Sunil Bahl, Rakesh Kumar, Sunil Shewale
Highlights
► Pentavac®vaccine demonstrated an excellent and long-lasting immune response. ► Quadrovax®vaccine induces good anamnestic response to all vaccine components. ► Quadrovax vaccine was well tolerated by all vaccinees. ► No serious adverse event was reported in either group. ► Pentavac is inexpensive and is a good alternative to other costlier similar vaccines.
Short communication
5. A ntibody persistence and the effect of a booster dose given 5, 10 or 15 ye ars after vaccinating preadolescents with a recombinant hepatitis B vaccine
Pages 448-451 Vladimir Gilca, Gaston De Serres, Nicole Boulianne, Donald Murphy, Philippe De Wals,
56 Manale Ouakki, Gisele Trudeau, Richard Massé, Marc Dionne
Highlights
► Persistence of antibody and the effect of a booster dose were monitored. ► Anti-HBs persist for at least 15years post-primary vaccination. ► Excellent immune memory was observed in virtually all vaccines. ► Challenge doses induced long-lasting high anti-HBs titres. ► The results indicate no need in booster doses for at least 15years post- vaccination.
Reviews
6. Immune responses and protection in children in developing countries induced by oral vaccines Review Article
Pages 452-460 Firdausi Qadri, Taufiqur Rahman Bhuiyan, David A. Sack, Ann-Mari Svennerholm
Highlights
► Children in developing countries need different dosage/regimes of oral vaccines. ► Ty21a vaccine induced serum and mucosal B and T-cell responses were observed. ► Administration of rotavirus and OPV may lower the response to rotavirus vaccine. ► Zinc has positive effect to immune response to Dukoral and pneumococcal vaccine.
7. Immune evasion strategies of flaviviruses Review Article
Pages 461-471 Jing Ye, Bibo Zhu, Zhen F. Fu, Huanchun Chen, Shengbo Cao
Highlights
► Flaviviruses have evolved a variety of strategies to modulate the immune responses of host. ► Mechanisms by which flaviviruses evade the innate and adaptive immunity of the host are summarized based on current studies. ► Flaviviruses limit type I IFN signaling by blocking the host gene expression, thus attenuating innate immunity. ► Flaviviruses also inhibit the antiviral immune response of complement system and NK cells. ► High genetic variability of viral antigens allows viral escape from both humoral and cellular immunity against flaviviruses.
Regular papers
8. Enhancement of HIV-1 DNA vaccine immunogenicity by BCG-PSN, a novel adjuvant Original Research Article
Pages 472-479 Jing Sun, Jue Hou, Dingfeng Li, Yong Liu, Ningzhu Hu, Yanling Hao, Jingjing Fu, Yunzhang Hu, Yiming Shao
57 Highlights
► We found that BCG-PSN could significantly improve the immunogenicity of DNA vaccine when co-administered with DNA vaccine. ► DNA vaccine co-administrated with BCG-PSN could decrease 10-fold dose of vaccine requirement. ► Our results demonstrate that BCG-PSN can activate TLR signaling pathways and induce Th1-type cytokines secretion. ► Our results may provide valuable information for designing an effective HIV-1 DNA vaccine immunization strategy. 9. The potential economic value of a cutaneous leishmaniasis vaccine in seven endemic countries in the Americas Original Research Article
Pages 480-486 Kristina M. Bacon, Peter J. Hotez, Stephanie D. Kruchten, Shaden Kamhawi, Maria Elena Bottazzi, Jesus G. Valenzuela, Bruce Y. Lee
Highlights
► We constructed and utilized a computer simulation model to evaluate the economic value of a CL vaccine. ► Modest protection duration and efficacy are required for CL vaccination to cost less than treatment. ► A preventative CL vaccine could save costs at moderate levels of infection risk. 10. A PCV2 vaccine based on genotype 2b is more effective than a 2a-based vaccine to protect against PCV2b or combined PCV2a/2b viremia in pigs with concurrent PCV2, PRRSV and PPV infection Original Research Article
Pages 487-494 Tanja Opriessnig, Kevin O’Neill, Priscilla F. Gerber, Alessandra M.M.G. de Castro, Luis G. Gimenéz-Lirola, Nathan M. Beach, Lei Zhou, Xiang-Jin Meng, Chong Wang, Patrick G. Halbur
Highlights
► Commercial PCV2 vaccines are based on PCV2a; most field infections are due to PCV2b. ► PCV2 vaccines based on genotypes 2a and 2b were compared. ► PCV2b vaccination was more effective in the experimental pig model. ► PCV2a and PCV2b coinfection resulted in clinical manifest disease. 11. E valuation of 238 antigens of L eptospira borgpetersenii serovar Hardjo for protection against kidney colonisation Original Research Article
Pages 495-499 Gerald L. Murray, Miranda Lo, Dieter M. Bulach, Amporn Srikram, Torsten Seemann, Noelene S. Quinsey, Rasana W. Sermswan, Andy Allen, Ben Adler
12. The impact of maternally derived immunity on influenza A virus transmission in neonatal pig populations Original Research Article
Pages 500-505 Matt Allerson, John Deen, Susan E. Detmer, Marie R. Gramer, Han Soo Joo, Anna Romagosa, Montserrat Torremorell
58 13. Hepatitis B specific T cell immunity induced by primary vaccination persists independently of the protective serum antibody level Original Research Article
Pages 506-513 Maria Carollo, Raffaella Palazzo, Manuela Bianco, Elisabetta Pandolfi, Paola Chionne, Giorgio Fedele, Alberto Eugenio Tozzi, Rita Carsetti, Luisa Romanò, Clara Maria Ausiello
Highlights
► Concerns about immunogenicity of hepatitis B virus component of Hexavac vaccine. ► T response to establish differences in Hexavac/Infanrix primary vaccinated children. ► Both vaccines are efficient in generating T recall responses 5 years after vaccination. ► Less immunogenic Hexavac induces strong HBsAg recall proliferation/memory subsets. ► Cellular immune and serological responses are important as surrogate of protection. 14. Voluntary reporting of health care personnel seasonal influenza vaccination rates and the impact of universal policies in Illinois hospitals Original Research Article
Pages 514-517 Bonnie Paris, Tracey Arahood, Carl Asche, Gail Amundson
Highlights
► We describe health care personnel seasonal influenza vaccination rates in Illinois hospitals over 3 years. ► Employees vaccinated earlier in the influenza season have greater benefit over time. ► Public reporting may contribute to universal employee vaccination policy adoption. ► Universal policies result in higher vaccination rates than voluntary programs. 15. Influenza vaccination in Turkey: Prevalence of risk groups, current vaccination status, factors influencing vaccine uptake and steps taken to increase vaccination rate Original Research Article
Pages 518-523 Meral Akcay Ciblak
Highlights
► This study shows that there are about 27–33 million people in risk groups in Turkey. ► Vaccines are provided to the HCWs free of charge and vaccination charges are reimbursed for the risk groups. ► The vaccination coverage rate is low in all risk groups especially in the elderly. ► Major absticle before the vaccination was disbelief in the vaccine effectiveness. ► A stakeholder network, Grip Paltformu, including MoH was established to combat flu effectively. 16. Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine Original Research Article
Pages 524-532 Gregory M. Glenn, Gale Smith, Louis Fries, Rama Raghunandan, Hanxin Lu, Bin Zhou, D. Nigel Thomas, Somia P. Hickman, Eloi Kpamegan, Sarathi Boddapati, Pedro A. Piedra
59 Highlights
► This Phase 1 trial evaluated the safety and immunogenicity of an RSV (F) nanoparticle vaccine. ► The vaccine was well-tolerated and no related SAEs were observed. ► Both RSV A and B microneutralizating antibodies were increased in vaccinees versus placebo. ► There was a 7- to 19-fold increase in anti-F IgG and a 7- to 24-fold increase in palivizumab-like antibodies. ► The levels of immunity are similar to those seen in other settings with decreased hospitalizations. 17. Waning immunity to measles in young adults and booster effects of revaccination in secondary school students Original Research Article
Pages 533-537 Hanqing He, En-fu Chen, Qian Li, Zhifang Wang, Rui Yan, Jian Fu, Jinren Pan
Highlights
► The population immunity did not reach the presumed thresholds of measles elimination. ► The significant decay of antibody against measles was found since adolescences. ► Secondary school students can acquire sufficient immunity to measles after revaccination. ► Revaccination program can be conducted effectively and practically in secondary school. 18. Comprehensive evaluation of the adenovirus/alphavirus-replicon chimeric vector-based vaccine rAdV-SFV-E2 against classical swine fever Original Research Article
Pages 538-544 Yuan Sun, Da-Yong Tian, Su Li, Qi-Lin Meng, Bi-Bo Zhao, Yongfeng Li, Dan Li, Li-Jun Ling, Ya-Jin Liao, Hua-Ji Qiu
Highlights
► The chimeric vector-based vaccine rAdV-SFV-E2 was safe for mice, rabbits and pigs. ► Low dose or single immunization with the vaccine provided full protection from CSF. ► Anti-CSFV antibodies or pre-immunization with the vaccine did not affect its efficacy. ► The vaccine administered alone or together with PRV vaccine induced equal protection. 19. TAT-mediated gp96 transduction to APCs enhances gp96-induced antiviral and antitumor T cell responses Original Research Article
Pages 545-552 Bao Zhao, Yanzhong Wang, Yu Zhang, Yang Li, Xiaojun Zhang, Yaxing Xu, Lizhao Chen, Changfei Li, Ying Ju, Songdong Meng
Highlights
► We designed a more efficient approach to improve the adjuvant functions of gp96. ► The cell-penetrating peptide TAT increased gp96 internalization into macrophages. ► TAT-based gp96 delivery increased gp96-induced T cell responses. ► TAT fusion remarkably enhanced gp96-mediated antiviral efficiency. ► TAT fusion significantly enhanced gp96-mediated antitumor activity. 20. Bluetongue virus serotype 8 virus-like particles protect sheep against virulent virus
60 infection as a single or multi-serotype cocktail immunogen Original Research Article
Pages 553-558 Meredith Stewart, Eric Dubois, Corinne Sailleau, Emmanuel Bréard, Cyril Viarouge, Alexandra Desprat, Richard Thiéry, Stéphan Zientara, Polly Roy
Highlights
► Development of Bluetongue virus-like particle (BTV VLP) for serotype 8. ► Assessment of BTV-8 VLPs as protective immunogen in sheep. ► No interference of immunogenicity in sheep vaccinated with VLP-cocktail. ► Multiple VLP vaccine protects sheep against BT disease. 21. Safety and immunogenicity of recombinant Rift Valley fever MP-12 vaccine candidates in sheep Original Research Article
Pages 559-565 John C. Morrill, Richard C. Laughlin, Nandadeva Lokugamage, Roberta Pugh, Elena Sbrana, William J. Weise, L. Garry Adams, Shinji Makino, C.J. Peters
Highlights
► We tested 2 recombinant RVF MP-12 vaccine candidates in 30- to 50-day pregnant ewes. ► No abortions or fetal abnormalities were observed. ► The arMP- 12ΔNSm21/384 candidate was immunogenic and safe in pregnant ewes. ► A dose of 1×103PFU stimulates a PRNT80response comparable to higher doses.
61